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ABSTRACT 
 
Inflammation and immune responses have been shown to contribute to a number pathological 
conditions - including those neurodegenerative diseases which affect the brain. Microglial 
cells represent the resident immune cell population that constitute the immune system of the 
CNS. Acetylation of proteins is one of the chemical modifications by which microglial cells 
regulate the transcription of genes that respond to pro- and anti-inflammatory signals through 
multiple pathways. In addition to acetylation, the intensity and duration of the inflammatory 
response is regulated by changes in the phosphorylation state of the signaling pathways 
involved in the regulation of inflammation. 
One of the major intracellular cell-signaling pathways for inflammation, the NF-κB system, 
regulates the expression of many genes involved in immune responses. The transcriptional 
response of intranuclear NF-κB is also tightly regulated, not only by post-translational 
modifications of  NF-κB itself but also by modification of histones. The dynamic switches 
between activity states of chromatin are modified by the interplay of two competing 
enzymatic activities, histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
which regulate the acetylation state of proteins. By counteracting the effects of HATs at the 
site of inflammatory gene transcription, HDACs play a major role in the regulation of the NF-
κB-dependent inflammatory response. 
Our aim was to shed light on changes occurring in the regulation of the inflammatory 
response by manipulating the acetylation and phosphorylation status of different neural 
inflammation models. The pro- and anti-inflammatory responses were characterized using 
established cell culture models. 
The results show that an increase in the level of protein acetylation, as well as enhancement of 
protein phosphorylation, leads to a proinflammatory response. The potentiated response by 
hyperphosphorylation occurred earlier than the acetylation induced response. Moreover, the 
inflammatory response showed a synergistic potentiation when both acetylation and 
phosphorylation were enhanced simultaneously with compounds affecting separate pathways, 
indicating that different signaling pathways govern the overall acetylation and 
phosphorylation mediated immune responses. The proinflammatory responses could be 
inhibited by using specific blockers targeted against the different signaling pathways. 
This thesis provides more insight into the research, development and characterization of anti-
inflammatory drug candidates that are targeted to modulate the HAT-HDAC balance, 
phosphorylation status and  the regulation of NF-κB pathway 
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  "A man should keep his little brain attic stocked with all  the furniture 
  that he is likely to use, and the rest he can put away in the lumber-room 
  of his library, where he can get it if he wants it." 
              
               -Sir Arthur Conan Doyle- 
             
               (Sherlock Holmes in "The Five Orange Pips") 
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1. INTRODUCTION 
 
 
Surely none of us at one time or another has been able to escape the grasp of infection as 
we continuously battle against "invaders". Fortunately, our body is endowed with a defence 
mechanism that, in most of the cases, wins the fight and the inflamed tissue heals quickly. This 
complex defence mechanism is called the immune system and has evolved to protect us from 
the attack of the "invaders"- millions of bacteria, viruses, parasites and toxins- that constantly 
try to find their way into our body. 
Like the rest of the body, the brain also is challenged by proinflammatory mediators. If 
things go awry these substances can damage and/or cross the blood-brain barrier - "the 
firewall"- and these inflammatory agents are known to play an important role in a wide 
number of disorders. Indeed, an increasing number of individuals are suffering from aging-
associated diseases that affect the brain as we live longer than intended in our "evolutionary 
design". These neurodegenerative diseases, such as Alzheimer's disease (AD), represent a 
huge challenge to the scientists trying to discover better therapeutics to prevent, cure or slow 
down the disease processes. 
The past 15-20 years of intensive basic and clinical research has revealed that inflammation 
and inflammatory responses significantly contribute to the pathogenesis of neurodegenerative 
diseases. Thus, a better understanding of the immunoregulatory systems of the brain may 
represent the key to finding novel anti-inflammatory approaches, e.g. identifying novel drug 
candidates for the treatments of these devastating disorders. 
Acetylation of histone proteins is one of the chemical modifications by which the cells 
regulate the transcription of genes that respond to the pro- and anti-inflammatory signals 
mediated through multiple pathways. This is a phenomenon which is ubiquitous in all 
eukaryotic cells. While it is rarely possible to perform invasive studies in the human brain, 
many cell culture and animal models have been generated to reveal the principle regulatory 
mechanisms of the cells involved in the inflammatory responses within the central nervous 
system. 
The present thesis deals with the question of how histone deacetylase inhibitors regulate the 
microglial inflammatory responses. The pro- and anti-inflammatory responses were 
characterized using established cell culture models. An organotypic slice culture model was 
established, refined and characterized for these studies.  Rat hippocampal slices were used to 
compare the results from straightforward cell culture studies with a culture model that mimics 
the response of the whole tissue. 
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2. REVIEW OF THE LITERATURE 
2.1 Brain inflammation 
The defence battle 
As diverse as life is, one exceptionally common phenomenon unites all life forms from 
plants to humans, i.e, the immune system. This system, or network, has evolved to fight 
against pathogens and in that way to protect the individual. The constant struggle against 
bacteria, viruses and other pathogens would be a "lost cause" unless the immune system could 
not counterattack against its myriad of enemies via a variety of inflammatory responses. These 
responses, as we understand today, are orchestrated by a network of complex chemical and 
molecular interactions in order to limit tissue damage and to facilitate rapid recovery and 
tissue healing. 
Similarly to the rest of the human body, the brain also needs protection. The neurons are 
fragile and sensitive to insults and the maintenance of the neuronal well-being is truly a matter 
of life and death. To facilitate the control of the internal milieu of the brain, the CNS is 
protected by the blood-brain barrier (BBB) which serves as a "gateway" that controls the entry 
of peripheral infiltrates. The blood-brain barrier is a specialized system of miles of narrow 
capillaries throughout the brain, all filled with tightly-packed endothelial cells that are 
exceedingly selective in determing which compounds gain access to the brain and which are 
excluded. Together with immune cells of the brain, the BBB forms the defence system that 
confronts and combats the threats (Figure 1).  
 
 
SKULL
BLOOD BRAIN BARRIER
TIGHT SEAL OF CELLS
BRAIN
MICROGLIA
ASTROCYTES
TIGHT SEAL OF CELLS
 
 
 Figure 1. The Blood Brain Barrier
 
The cellular locus of the the Blood Brain 
Barrier is the endothelial cell of the 
brain capillary. The specialized system
of membranes of the brain capillary 
endothelial cells forms a biological 
interface between the local blood vessels 
and most parts of the central nervous 
system. This physical barrier protects 
the brain by stopping many substances 
from travelling across it. Astrocyte end-
feet encircle endothelial cells and 
microglia are localized at a site close to
the Blood Brain Barrier. 
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Death of a Dogma 
For nearly a century one general belief in the field of neuroscience was that the mammalian 
brain is an "immunologically privileged" organ, i.e. completely separated from the immune 
system of the rest of the body (Dermietzel et al., 2006). The blood-brain barrier - "the firewall"  
of central nervous system - was thought to prevent entry of harmful molecules into the CNS 
parenchyma and thus was responsible for maintaining homeostatis within the brain. This of 
course still holds some seeds of the truth but every now and then, as so often happens in 
science, the traditional views need to be revised. Recent applications of modern research 
techniques have provided new information in the field of neuroinflammation. It is known that 
the capability of the CNS to tolerate all consequences of the defence battle is limited and 
excessive insults can lead to destruction or compromise of the blood-brain barrier 
(Andjelkovic and Pachter, 1998). However, the brain and the immune system are known to 
communicate with one another and today it is recognized that the CNS possesses a capacity to 
mount an immune response.  
Intensive neuroinflammation research focusing on the brain macrophages, i.e. the 
microglial cells, has led to the wide acceptance that these cells truly represent a resident 
immune cell population that constitute the immune system of the CNS (Streit, 2002, van 
Rossum and Hanisch, 2004). There is evidence that microglia and perivascular macrophages 
"talk to each other". Moreover, under pathological conditions, microglia are capable of 
secreting cytokines and serving as antigen-presenting cells (APCs) (Hanisch, 2002), thus 
sharing properties with the monocytes in the periphery. 
Indeed, over the last 15-20 years, neuroimmunologists have presented many examples of 
immunological responses to brain antigens, neuronal expression of major histocompatibility 
complex (MHC) class I genes, microglial expression of MHC class II genes, and also 
neurological autoimmunity has been recognized (Nakajima and Kohsaka, 2004, Perry,1998, 
Rivest S, 2003, Shrikant and Benveniste, 1996).  
Thus, our original impression of an "immunoprivileged" status of the brain must be 
qualified by stating that this depends on conditions. The brain clearly has some inimitable 
immunologic properties, and thus the claim that it is isolated from the immune system is a 
fallacy. 
 
 
 
 18
The Affected Brain 
The remarkable power of the protection provided by immune system comes at a cost, the 
inflammatory response has also the capacity to evoke damage. The consequences of an 
overwhelming inflammatory response are not always predictable and nowadays it is agreed 
that dysregulation of the innate or acquired immune response is involved in different brain 
pathologies (Marchetti and Abbracchio, 2005).  
Multiple sclerosis (MS) has long been recognized as an inflammatory disease of the brain 
(O'Connor et al., 2001). In this devastating disease, vascular inflammatory infiltrates can cause 
breakdown of the blood–brain barrier which in turn leads to demyelination, gliosis, axonal 
damage, varying degrees of edema etc. and eventually to permanent neurological disability 
(Hafler et al., 2005).   
In recent years it has also been suggested that a chronic or overwhelming inflammatory 
response may contribute to other CNS diseases such as stroke, traumatic brain injury, HIV-
related dementia, Alzheimer's disease, Parkinson's disease and prion disease (Kadiu et al., 
2005). The recognition of the various inflammatory components involved in the pathology of 
these different diseases has emerged from the new techniques and reagents available for 
studying inflammation mechanisms in brain pathology (Buckwalter and Wyss-Coray, 2004).  
The brain in Alzheimer's disease exhibits a chronic inflammatory response characterized by 
activated glial cells and increased expression of cytokines and complement factors 
surrounding the amyloid deposits (McGeer and McGeer, 2003). Similarly, reactive microglia 
and the presence of activated complement proteins have been demonstrated in the affected 
brain regions in Parkinson's disease (Hague, Klaffke and Bandmann, 2005).  
One of the acute phase proteins of the complement system, the C-reactive protein (CRP), is 
considered to be one of the critical inflammatory markers (Vermeire, Assche and Rutgeerts, 
2005). Together with other markers, such as cytokines, increased levels of peripheral CRP 
have been shown to be associated with increased risk of incident stroke (Kuo et al., 2005). 
Evidence is also being gathered to suggest that aged individuals with chronic inflammation, as 
well as those with chronic or acute infections, are at an elevated risk of suffering from multiple 
degenerative diseases. There is an increasing body of evidence that the resident macrophages 
of the central nervous system, i.e. the microglial cells, play a very crucial part in most of the 
brain disorders (Streit et al., 2005) and neuroinflammation together with microglial pathology 
contribute to the severity of these diseases. 
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Microglia: the frontline cells 
The smallest cell population of glial cells in the brain, the microglia, were originally 
distinguished from other CNS supporting cells by del Rio-Hortega (del Rio-Hortega, 1932). In 
the 1980's, with a development of cell staining techniques, it was shown that these cells are 
related to macrophages and account for up to 20 % of the total glial cell population, and that 
they uniformly scattered throughout the adult brain (Barron, 1995, Jordan and Thomas, 1988, 
Kreutzberg, 1996, Lawson et. al., 1991, Moore and Thanos, 1996, Perry and Gordon, 1988, 
Streit, 2001). Today, microglia  are considered to be derivatives of the hematogenous 
monocyte/macrophage lineage of mesodermal origin (Kaur et al., 2001, Ling et al., 2001). 
They enter the brain in early development and appear to form two (sub)populations, one of 
"resident" microglia (a.k.a. "parenchymal" or "juxtavascular") that form a relatively stable 
population associated with the microvessels, but these cells are also able to migrate through 
the brain parenchyma, and "perivascular" microglia/macrophages that are enclosed by the 
basement membrane of the vessel wall (Gehrmann et. al., 1995, Lassman et. al., 1991. Mato 
et. al., 1986, 1996). Furthermore, they represent a dynamic population able to exchange with 
the monocytes in the blood (Gehrmann et. al., 1995, Grossmann et al., 2002, Guillemin G. and 
Brew B., 2004, Nakajima and Kohsaka, 2004). 
Microglia possess the potential to undergo dramatic morphological and functional changes 
from "resting" ramified forms to "activated" amoeboid cells (Figure 2.). Recent studies indicate 
that microglia cells actually never rest but instead they constantly monitor their immediate 
environment by extending and retracting their projections over a minute-to-minute time scale, 
thus performing an immune surveillance role (Nimmerjahn et al., 2005, van Rossum and 
Hanisch, 2004). Activated microglia have been shown to secrete a host of proinflammatory 
soluble factors such as cytokines, free radicals and fatty acid metabolites ( Giulian et al., 
1994b, Lee et. al, 1993, Prinz et. al., 1999, Smith et. al., 1998), all of which are thought to be 
harmful to neurons. For example, loss of dopaminergic neurons in rat substantia nigra has 
been shown to be mediated via microglial activation (Arimoto and Bing, 2003). Furthermore, 
dying neurons release factors that may stimulate microglia and astrocytes to produce more 
cytokines ( Ferrari et al., 1997, Hide et al., 2000, Liu et al., 2000), leading possibly to a cycle 
of chronic stimulation of these cells. On the other hand, microglia are thought to possess a 
supportive and protective role. There is evidence that microglia are able to deliver growth 
factors and remove cell debris from injured neurons (Elkabes et al., 1996, Nakajima et al., 
2001, Nakajima and Kohsaka, 2004). It has also been demonstrated in live hippocampal slice 
cultures that microglia rapidly engulf any dead cells in their nearby vicinity (Petersen and 
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Dailey 2004).  So, while these cells appear to be there to battle against microbial attacks and to 
protect the CNS from ischemic or traumatic injury, they do seem to inflict brain damage when 
they are overburdened. Therefore, the role of microglial activation may be described as a 
"double-edged sword". Whereas some growth factors secreted by reactive microglia may 
promote the repair phase after brain trauma, several cytotoxic molecules produced by these 
cells might affect the well-being and survival of damaged neurons. 
 The innate immunity in the brain is mainly the responsibility of the microglial cells (Olson 
and Miller, 2004). Cell surface receptors that mediate immune responses as well as 
intracellular transcription factors that regulate inflammatory responses have been identified in 
these cells. There is also extensive evidence that microglia interact with other immune cells 
(Deng and Sriram, 2005, Giuliani, Hader and Yong, 2005, Markovic et al., 2005) and these 
complex interactions are tightly regulated within the immune system. The dynamic nature of 
microglia allows these cells to move around in the CNS parenchyma, especially to any site of 
infection, and therefore it is no great surprise that these cells can stimulate astrocytes and 
neurons. In addition, by extending their processes into the perivascular basement membrane, 
microglia can directly make contact with the pericytes and endothelial cells of the BBB. The 
literature contains an abundance of evidence for the great variety of effects induced by 
microglia (for a review see (Farber and Kettenmann, 2005)),  but the role of these cells in the 
regulation of the endothelium and the permeability of the blood-brain barrier is still poorly 
understood. It has been proposed that microglia, together with astrocytes, release factors that 
may promote endothelial cell growth and survival (Prat et al., 2001). Activation of microglia  
has also been suggested to evoke an in situ inflammatory reaction that may modulate BBB 
function as well  causing injury, even death, of endothelial cells.  
Moreover, one has to take into account the bi-directional interaction of microglia with other 
brain cells, and that the other cell types surrounding the brain microvasculature also contribute 
to BBB integrity. Therefore the overall role of microglia as an immune- or immunoeffector 
brain macrophage appears to have a dualistic nature. On one hand, microglia play a role in 
facilitating functional plasticity of CNS and seem to act as the primary sensor for insults but 
on the other hand, excessive microglial activation can lead to severe brain damage. As a 
whole, activated microglia appear to play a significant role in inflammatory states of the brain, 
expressing both or either cytotoxic and neurotrophic functions. Since microglia can produce a 
wide range of biologically active molecules which can result in either beneficial or detrimental 
outcomes, therapeutic interventions targeted on microglia and their products may open new 
avenues for controlling inflammatory brain diseases. 
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 Figure 2.
 
A. Microglial cell showing          
typical "resting", ramified 
morphology with small cell 
body and branching 
processes. 
B. "Reactive" microglia with a 
rounded,"amoeboid" 
phenotype. 
     Picture: Jari Huuskonen © 
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2.2 Innate immunity 
Running in the blood 
Although it can be concluded from early writings that man knew about disease and its 
ravages, the history of immunity (L: immunis – free of) and immunology goes back to the 
“Fathers of Immunology”- Louis Pasteur (1882-1895) and his fellow Pastorians Ilya I. 
Mechnikov (a.k.a. Elias Metchnikoff, 1845-1916) and Paul Ehrlich (1854-1915). After 
observing that the "mobile cells"of transparent larvae of starfish accumulated around lesions, 
Mechnikov considered that these cells might participate in defense system of these organisms 
(Metchnikoff, 1884). To test the value of his hypothesis he carried out further experiments 
with the transparent water flea Daphnia and in that way discovered phagocytosis, a 
phenomenon which laid the foundation for the theory of cell-based immunity. At the same 
time, his friend Ehrlich proposed his side-chain theory of immunity – immunity was due to 
humoral substances, i.e. antibodies, and together with Mechnikov they shared the 1908 Nobel 
Prize in Physiology or Medicine for their "work on immunity". 
However, the field of innate immunity was more or less left in the doldrums until the the 
late 1950’s and early 60's  when T and B cells became recognized. Those years are 
characterised in the literature  as the beginning of modern immunology. The basis for humoral 
and cellular immunity was proven beyond reasonable doubt but the development of molecular 
and genetic techniques in the past decades has truly remodeled and deepened our 
understanding of how the immune system operates.  
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One of the latest breakthroughs of innate immunity saw daylight in 1989 when Charles A. 
Janeway wrote a paper about his idea of how the immune system alerts the body's T and B 
cells (Janeway, 1989). Sadly his paper was largely ignored by the scientific community for 
some time but together with young Russian biochemist Ruslan Medzhitov they were able to 
unveil the molecular scouts that today have proved to be the key players in the theory of 
"Pattern Recognition Hypothesis" (Medzhitov and Janeway, 2000b, Medzhitov and Janeway, 
2000c). 
Today, the term innate immunity is used to describe the defence mechanisms that, in a non-
specific manner, respond to the attack of pathogenic organisms. In addition to the physical 
barrier, the skin, the innate immune system is composed of specialized cells that are able to 
detect, recognize and respond to pathogens. The cells involved in this counterattack are the 
white blood cells and macrophages that express specialized receptors, e.g. the microglia in the 
brain.  
 
The Road to Toll 
Janeway and Medzhitov coined the phrase "first line of defence" (Janeway and Medzhitov, 
2002) which is nowadays a widely used term to describe the innate immune system. This 
evolutionary ancient system operates through a broad range of defence mechanisms that 
recognize invariant molecular structures of pathogens. These molecular structures, called 
"pathogen-associated molecular patterns (PAMPs)" (Medzhitov and Janeway, 2000a), are 
detected by the cells of the immune system.  
In order to be able to elicit a rapid and appropriate defensive response, a large number of 
potential microbial pathogens need to be discriminated from non-infectious self.  
Nature has met this challenge by the evolution of a variety of germ-line encoded cell-
surface receptors called  Toll-like receptors (TLRs), originally identified from the fruit fly 
Drosophila (Hashimoto, Hudson and Anderson, 1988).  Monocytes, macrophages and their 
derivatives (i.e. microglia in the brain) express these receptors that are referred to as "pattern-
recognition receptors (PRRs)" (Medzhitov and Janeway, 2000a). These receptors are type I 
transmembrane receptors that function as either homodimers or they may form heterodimers 
with another TLR. They are generally divided into three groups; 1) secreted molecules that 
circulate in blood and lymph; 2) surface receptors on phagocytic cells such as macrophages 
that bind the pathogen prior to engulfment, and; 3) cell-surface receptors that bind the 
pathogen initiating a signal leading to the release of effector molecules (cytokines). 
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The mammalian TLR family shares common structural features: multiple leucine-rich 
repeats and one or two cysteine-rich regions in the large and divergent ligand-binding 
ectodomain; a short transmembrane region; and a conserved cytoplasmic domain that is highly 
homologous among the individual TLRs and contains a Toll/IL-1R (TIR) domain similar to 
the cytoplasmic domain of the interleukin 1 receptor (IL-1R) (Figure 3.). Of the eleven 
mammalian TLRs described so far (as of September 2006), the ligands for ten of the receptors 
have been identified (Table 1.).  Each TLR  has a specific ligand, but for a full sensitivity they 
may also depend on other co-receptors, for example in the case of TLR4's, recognition of 
molecular structure of Gram negative bacteria (see Figure 4.) 
The PRRs perform their role by mediating phagocytosis or they can function as signal-
transducers. Phagocytosis leads to killing and degradation of infectious agent within the 
maturing phagosome and delivery of cytokines, thus triggering the inflammatory response. As 
signal-transducers, the PRRs are capable of inducing transmembrane signals that activate 
intracellular pathways. A common pro-inflammatory pathway involved in the activation of the 
host defence, the nuclear factor kappa B (NF-kB), is one of the first downstream signaling 
pathways that was linked to Toll-like receptor pathways (Hawiger J, 2001, Medzhitov and 
Janeway, 1999) and intensive work in the field has revealed the connection of many other 
inflammatory pathways to Toll signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A common structure of the 
mammalian TLRs. 
The TLRs contain intracellular domains 
homologous to those of the IL-1 receptor and 
also contain extracellular leucine-rich repeats 
and one or two cysteine-rich regions. 
Activation of intracellular domain leads to 
activation of different signaling pathways that 
modulate the innate immune responses. 
(Adapted and modified from Cario, 2003). 
Transmembrane domain 
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Table 1. Ligands for the activation of the different mammalian TLRs 
 
Receptor                Ligand PAMP(s) Reference 
TLR 1 triacyl lipoproteins Hornung et al.,  2002, Ozinsky et al.,2000 
TLR 2 
lipoproteins; gram positive 
peptidoglycan; lipoteichoid acids; 
fungi; viral glycoproteins 
Hertz et al., 2003, Komai-
Koma et al., 2004,  Underhill 
et al., 1999 
TLR 3 double-stranded RNA 
Guillot et al., 2005, Wang 
et al., 2004, Alexopoulou et 
al., 2001, Kariko et al., 2004 
TLR 4 lipopolysaccharide; viral    glycoproteins 
Hornef et al., 2003, 
Andonegui et al., 2002, 
Sabroe et al., 2003, Fan et al., 
2003, Roger et al., 2001, 
Ohashi et al., 2000 
TLR 5 flagellin 
Gewirtz et al., 2001, 
Didierlaurent et al., 2004, 
Hawn et al., 2003 
TLR 6 diacyl lipoproteins Hornung et al., 2002, Ozinsky et al., 2000 
TLR 7 small synthetic compounds;  single-stranded RNA Heil et al., 2004 
TLR 8 small synthetic compounds;  single-stranded RNA Heil et al., 2004 
TLR 9 unmethylated CpG DNA 
Sivori et al., 2004, Latz et 
al., 2002, Eaton-Bassiri et al., 
2004, Bauer et al., 2001 
TLR 10 unknown  
TLR 11 profilin-like molecule Yarovinsky et al., 2005 
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The Lipopolysaccharide connection 
The outer membrane wall component of Gram negative bacteria, lipopolysaccharide (LPS), 
is an endotoxin that triggers inflammation. Systemic administration of LPS is a generally used 
model of infection since it increases the release of proinflammatory cytokines by circulating 
monocytes and macrophages. The innate immune system in the brain recognizes LPS through 
Toll-like receptor 4 (TLR4) (Lee and Lee, 2002, Lehnardt et al., 2002) which is expressed by 
microglia. Circulating LPS first binds to LPS-binding protein (LBP) and the CD14 receptor, 
which are also expressed by microglia. TLR4 binds to this complex and evokes intracellular 
cascade of events that are regulated by a nuclear factor kappaB (NF-κB) signaling pathway. 
Activation of microglia and the subsequent pathway induced by LPS lead to release of 
cytotoxic factors such as nitric oxide and proinflammatory cytokines which can contribute to 
neurodegeneration (Lehnardt et al., 2003) (Figure 4.). Furthermore, LPS is involved in protein 
remodelling by inducing acetylation and phosphorylation of histones (Qin et al., 2005, 
Rahman, 2002). However, as the inflammatory response of microglia may be considered as 
the normal, defensive response of these cells, the injuries that result from bacterial infection 
might be more or less an unwanted bystander effect of microglial activation. 
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CD14 
 
 
 
 
TLR4
LBP
adaptor
proteins
NF-κB
INFLAMMATORY 
CYTOKINES
Figure 4.
A schematic drawing to illustrate 
the LPS induced NF-κB 
signaling pathway in microglia. 
LPS first binds to LPS-binding 
protein (LBP) and the CD14 
receptor. LBP and CD-14 
facilitate the presentation of LPS 
to MD-2, TLR4 binds to this 
complex and induces an 
intracellular cascade of events 
leading to production of 
inflammatory cytokines. 
MD-2
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2.3 NF-κB - The Intercity 
Preface 
In order to produce proteins the cell needs to transfer the genetic information, that is coded 
in the DNA, into a sequence of messenger RNA (mRNA) molecules. This process, called 
transcription, is followed by synthesis of proteins, i.e. translation. Transcription factors are 
proteins that are involved in the regulation of gene expression and thus they control the 
activation of transcription. Transcription factors are composed of two essential functional 
regions: a DNA-binding domain and an activator domain. The DNA-binding domain consists 
of amino acids that recognize specific DNA bases near the start of transcription. Transcription 
factors are typically classified according to the structure of its DNA-binding domain. The 
activator domains of transcription factors interact with the components of the transcriptional 
apparatus (RNA polymerase) and with other regulatory proteins, thereby affecting the 
efficiency of DNA binding. The regulation  by transcription factors takes place at specific 
sites, i.e., transcription begins at the promoter, which is a sequence specifying the beginning of 
transcription. It then proceeds through the coding region, a sequence that includes coding 
information for the polypeptide chain specified by the gene. The transcription ends at the 
terminator, a sequence that specifies the end of the mRNA transcript. (Stryer, 1995, Lachman, 
1995).  
 
Conductor of inflammation 
The eukaryotic nuclear factor kappaB (NF-κB), first described in 1986 (Sen and Baltimore, 
1986), is a general term used to describe a number of dimeric combinations of the Rel protein 
family members of gene regulators that possess transcriptional activating properties (Ghosh, 
May and Kopp, 1998). The mammalian NF-κB family members include p65 (RelA), RelB, c-
Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). Today, NF-κB is recognized as the major 
cell-signaling molecule for inflammation that regulates the expression of a number of genes 
involved in multi-level regulation of immune responses. For example, p65/TNFR1 double 
knockout mice exhibit increased susceptibility to bacterial infection (Alcamo et al., 2001),  
RelB-deficient mice show decreased baseline activity of NF-κB, a loss of cellular immune 
responses and deficits in adaptive immunity (Weih et al., 1995, Burkly et al., 1995). 
Furthermore,  a hypozygous mouse model of NF-κB-deficiency in which mice lack p50 and 
are heterozygous for p65 (p50–/–p65+/–; 3X), show increased sensitivity to LPS-induced shock 
(Gadjeva et al., 2004), a property of innate immune system. 
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Initial work carried out with animal models of systemic inflammation as well as studies 
applying brain-derived cell cultures have revealed that activation of NF-kB occurs in 
numerous tissues (Blackwell et al., 1994, Essani et al., 1996, Manning et al., 1995), including 
the brain (O'Neill and Kaltschmidt, 1997). Subsequent studies using different models have 
allowed identification of many of the mediators involved in the development of  inflammatory 
injuries. 
Central to activation of NF-κB and the subsequent inflammatory cascade is the 
translocation of NF-κB from cytosol to nucleus. NF-κB resides in the cytoplasm of 
unstimulated cells and its activity is tightly regulated by the interaction with its inhibitory IκB 
proteins, IκBα, IκBβ and IκBε . These inhibitory proteins are believed to mask the nuclear 
localization signals on  NF-κB subunits and thus  prevent their translocation. Furthermore, it 
has been suggested that there is a continuous shuttling of signaling molecules between nucleus 
and cytoplasm and therefore the state of localization is dynamic (Birbach et al., 2002, Huxford 
et al., 1998, Huang et al., 2000, Huang and Miyamoto, 2001, Johnson et al., 1999, Malek et 
al., 2001).  
Several different inflammatory stimuli release NF-κB from the inhibitor and the signaling 
cascade is activated, leading to the complete degradation of IκB. (Chen and Greene, 2004, 
Greene and Chen, 2004). Degradation of IκB is initiated upon phosphorylation by inhibitory 
kappa kinases (IKKs), followed by ubiquitination and further degradation through 26S 
proteasome machinery.  This process liberates NF-κB dimers from IκB complexes and allows 
NF-κB to move into the nucleus where it binds to its target genes, including IκBα, and 
regulates their transcription (DiDonato et al., 1996, Karin and Ben-Neriah, 2000). The NF-κB 
activation is terminated and its location reversed by newly synthesized nuclear IκBα, which 
removes NF-κB from its target genes and shuttles back to cytoplasm (Arenzana-Seisdedos et 
al., 1997) (Figure 5.). 
Acetylation has a significant role in the nuclear function of NF-κB since it determines 
whether it exists in an active or inactive state (Greene and Chen, 2004). Acetylated NF-κB is 
active and is resistant to the inhibitory effects of IκB. However, when NF-κB is deacetylated, 
IκB readily binds to NF-κB leading to its translocation into the cytoplasm (Arenzana-
Seisdedos et al., 1997, Chen et al., 2001). Moreover, acetylation of transcription factors has 
been shown to affect many cellular functions such as transcriptional activity, interactions with 
cofactors and subcellular localization of other proteins. 
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The transcriptional response of intra-nuclear NF-κB is also tightly regulated, not only by 
post-translational modifications of  NF-κB itself but also by modification of histones 
(Boekhoudt et al., 2003, Graham and Gibson, 2005) . Stimulation by LPS can lead to 
increased acetylation of the amino-terminals of the histone tails surrounding NF-κB target 
genes (Chen and Greene, 2004). These hyperacetylated histones interact with NF-κB via 
coactivators to promote its transcription machinery through chromatin remodelling, whereas 
impaired NF-κB activity can be achieved by deacetylation of these histone residues. When 
activated, the NF-κB proteins interact with the same co-activator and co-repressor molecules 
as histones (Ashburner, Westerheide and Baldwin, 2001). Together with the dynamic changes 
occurring in the NF-κB - histone gateway, these molecules act as the molecular switches that 
control gene transcription. 
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Figure 5. 
1. Upon stimulation, IκBα is phosphorylated by the IκB kinase complex, containing IKKα, 
IKKβ and IKKγ. 2. The liberated NF-κB (p50/RelA) enters into the nucleus where RelA is 
acetylated by p300/CBP. The transcription of multiple genes, including the IκBα gene, is 
activated. 3. Deacetylation of RelA by HDAC3 promotes the binding of RelA to IκBα  The 
newly synthesized IκBα protein enters the nucleus, removes NF-κB from its target genes, and 
takes it back to the cytoplasm to terminate the phase of NF-κB activation. (Adapted and 
modified from Chen and Greene, 2003 and Quivy and Van Lint, 2004). 
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2.4 Histone Post-translation 
 
Normally genes are wrapped up in a complex, ordered structure of proteins and DNA. 
These proteins that are packed into the nucleosomes and complexed with DNA in chromatin 
are called the histones (Ramakrishnan, 1997). The structural subunit of chromatin, the 
nucleosome, consists of 146 base pairs of DNA wrapped around an octamer of highly 
conserved proteins. Each nucleosome core consists of two copies of each of the histones: 
H2A, H2B, H3 and H4. They are found in the nuclei of all eukaryotic cells, one of the most 
important features of histones is that they are susceptible to chemical modification (Grunstein, 
1997). These post-translational modifications include acetylation, phosphorylation, 
methylation and ubiquitination and these changes occur on the N-terminal tails of core 
histones (Figure 6.a).  
In general, increased transcriptional activity of inflammatory genes is linked together with 
increased levels of histone acetylation (hyperacetylation) and conversely repression of gene 
expression is associated with decreased levels of acetylation (hypoacetylation). For example, 
activation of inflammatory genes involves opening up of the chromatin structure as a result of 
acetylation of core histones. This unfolding of chromatin becomes possible through the action 
of another group of proteins called "co-activators" and the interplay between these co-activator 
molecules allows transcription factors to bind to a variety of DNA sequences, which in turn 
leads to gene induction (Barnes P., Adcock I. and Ito, 2005). 
The mechanisms of how other modifications of core histones, such as phosphorylation, 
methylation and ubiquitination, interact with acetylation and with other transcription factors 
are largely unknown (Marmorstein and Roth, 2001) but recent studies have highlighted the 
importance of this research area (for a review see (Emre and Berger, 2006, Santos-Rosa and 
Caldas, 2005)). Further studies may lead to a better understanding of how genes are 
differentially regulated and how more specific gene manipulation might be produced in the 
future.  
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HATs and HDACs 
The dynamic switches between activity states of chromatin are affected by the interplay of 
two competing enzymatic activities, histone acetyltransferases (abbreviated as HATs) and 
histone deacetylases (HDACs), which convert the acetylation state of histone proteins. 
Acetylation of histones (neutralization of positive charges of the histone tails) is catalyzed by 
HATs and it typically enhances transcription by reducing the affinity between DNA and 
histones (relaxation of chromatin structure) whereas removal of acetyl groups from the lysine 
residues by HDACs results in chromatin condensation and this process usually leads to 
repression of the transcriptional activity of many genes (Figure 6.b). However, a number of 
studies have emphasized that acetylation dependent gene regulation is anything but 
straightforward. There are indications that HATs can also act as repressors and HDACs can 
also function as (co)activators (de Ruijter et al., 2003), implying that the effects of protein 
(de)acetylation can be bi-directional. Futhermore, it has been observed that HATs and HDACs 
may be involved in the modification of other proteins in addition to histones (Hubbert et al., 
2002, Juan et al., 2000). These proteins include transcription factors, such as the NF-κB (see 
previous chapter) and other key regulatory proteins involved in inflammation. 
Several different forms of HATs and HDACs have been characterized and at least five 
different protein families of HATs (Roth, Denu and Allis, 2001) and eighteen different human 
HDACs (Verdin, Dequiedt and Kasler, 2003) have been identified. Based on their intracellular 
localization, histone acetyltransferases are separated into two types. Type A HATs are 
localized in the nucleus where they function as transcriptional co-activators. Type B HAT 
(Hat1p) acetylates nascent core histones in the cytoplasm and is suggested to be involved in 
chromatin assembly (Qin and Parthun, 2006). HDACs fall into three classes of protein 
families: the classical HDAC family of two different phylogenetic classes, namely class I and 
class II, and the recently discovered SIR2 family (SIRT 1-7) of NAD+-dependent class III 
HDACs. 
 The prevalent substrates of HDACs are found in the nuclei of eukaryotic cells. In order to 
exert their function, HDACs co-localize into the nucleus together with other proteins or 
HDACs or in response to a nuclear localization signal (NLS). Some HDACs possess a nuclear 
export signal (NES), suggesting that they can also move to the cytoplasm. It has been also 
shown that class II HDACs are able to shuttle between the nucleus and cytoplasm in response 
to certain signals emitted from the neighbouring cells (Verdin, Dequiedt and Kasler, 2003). 
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Figure 6.a 
 
Post-translational modifications on the histone tails. Each nucleosome core consists of two 
copies of each of the histones: H2A, H2B, H3 and H4. These evolutionarily conserved 
proteins have a globular C-terminal domain critical to nucleosome formation and a flexible N-
terminal tail that protrudes from the nucleosome core. A=Acetylation: M=methylation: 
P=phosphorylation: U=ubiquitination (Santos-Rosa and Caldas, 2005) 
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igure 6.b 
 schematic drawing to illustrate the interplay between HATs and HDACs. HATs catalyze the
cetylation by adding acetyl groups to lysines in the N-terminal tails of histones (encircled). 
he dynamic activity of HAT-modified proteins is counteracted by HDACs. (Modified from: 
ttp://www.broad.mit.edu/chembiolab_schreiber/anims/index.htm)  
Inhibition of HDACs 
One well-founded view today is that many histone deacetylase inhibitors (HDACi) operate 
y blocking access of acetylated substrate to the active site (reversible or irreversible) of 
DAC (Drummond et al., 2005), though the specific routes, i.e. whether HDACi cause direct 
istone hyperacetylation within the promoter/enhancer regions of cytokine genes, remain to be 
larified. Generally, HDACi are known to be able to induce growth arrest, differentiation or 
poptosis of cancer cells in vitro and in vivo (de Ruijter et al., 2003). HDACi are capable of 
nhibiting HDACs with varying efficiencies (from the nanomolar to millimolar 
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concentrations). Inhibition of HDACs can result in a general hyperacetylation of histones, 
which in turn leads to relaxing of chromatin. This "decompacting" of condensed chromatin 
allows access so that the transcription factors can bind to DNA and therefore increased 
transcriptional activation becomes possible. 
 Over the years, many different types of HDAC inhibitors have been developed. There are 
many inhibitors known but the most potent discovered so far is trichostatin A (TSA) (Eickhoff 
et al., 2000, Herold et al., 2002, Mishra et al., 2001, Moreira, Scheipers and Sorensen, 2003). 
TSA is a fermentation product of the fungi Streptomyces and it was originally used as an anti-
fungal agent, but was later discovered to have potent proliferation-inhibitory properties against 
cancer cells. TSA belongs to the group of hydroxamic acids, and it has been shown to be 
effective at nanomolar concentrations in vitro. Another well known group of HDACi are the 
short-chain fatty acids (SCFAs) (Saemann, Bohmig and Zlabinger, 2002) such as butyrate, 
propionate and valerate. These compounds have been shown to be less efficient in their 
HDAC-inhibiting capability than TSA (act in the millimolar compared with nanomolar range), 
but they are also less toxic. Some cyclic tetrapeptide antibiotics form the third group of 
inhibitors, and these compounds are characterized by their complicated chemical structure and 
their high HDAC-inhibitory potential. Most of these compounds are products of bacteria or 
fungi, but some are chemically engineered combinations of hydroxamic acids and cyclic 
tetrapeptides. Benzamides comprise the fourth group of the established histone deacetylase 
inhibitors. 
Some of the compounds mentioned above have entered into clinical trials  and an increase 
in histone acetylation has been observed (Chen, Faller and Spanjaard, 2003). Although little is 
known about the specific functions of the individual HDACs and the specific consequences of 
using HDACi in normal cells, the results achieved in these clinical trials might contribute 
greatly to enhancing our understanding of HDAC function and the therapeutic possibilities 
offered by these enzyme systems. Therefore studies investigating the mechanisms of actions of 
all HDACs and the effects of using HDACi are of clinical importance. A summary of the 
HDACi classes and their characteristics is presented in table 3. 
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Table 3. Molecular characteristics and clinical trial status of HDACi 
Class 
 
Compound 
 
 
 effect. 
(range) 
 
HDAC 
specificity 
 
Clinical trials; reference 
 
 
Short-chain 
 fatty acids 
Butyrate mM Class I, IIa Phase I, II; Bhalla, 2005 
 
Valproic acid 
(VPA) 
 
mM Class I, IIa Phase I, II; Bhalla, 2005 
 
Hydroxamic 
acids 
 
Trichostatin A  
(TSA) 
nM Class I, II N/A; Bhalla, 2005 
 
 
Suberoylanilide  
hydroxamic 
acid  
(SAHA) 
µM Class I, II 
Phase I, II, III (pre -
registration) ; 
Bhalla, 2005 
  PXD101 µM Class I, II Phase I; Bhalla, 2005 
  LAQ824 nM Class I, II Phase I; Bhalla, 2005 
  LBH589 nM Class I, II Phase I; Bhalla, 2005 
 Pyroxamide µM 
Class I, 
unknown effect  
on class II 
Phase I; Butler et al., 2001 
 SK-7041 nM HDACs 1 and 2 N/A; Park et al., 2004 
 SK-7068 nM HDACs 1 and 2 N/A 
 CG-1521  µM N/A N/A 
 Tubacin  µM Class IIb N/A; Haggarty et.al., 2003 
Benzamides MS-275 µM 
 
HDACs 1, 2,3, 
8 (marginally)  
 
Phase I, II; Hu et al., 2003 
 
Cyclic  
tetrapeptides 
Depsipeptide nM Class I Phase I, II; Furumai et at., 2002 
 Trapoxin A nM Class I, IIa N/A; Bhalla, 2005 
 Apicidin nM 
 
HDACs 1 and  
3, not HDAC8 
 
N/A; Vannini et al., 2004 
 
N/A; not available. effect.; effectiveness. Table modified from Bolden et al., 2006 
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HDACs and NF-κB mediated inflammation 
The level of the inflammatory response is clearly dependent on the activation state of 
numerous pathways, one of the major pathways being the transcription factor NF-κB. By 
counteracting the effects of HATs at the site of inflammatory gene transcription, HDACs play 
a significant role in the regulation of NF-κB-dependent inflammatory response. Generally, 
HDACs, together with co-repressors, repress the expression of NF-κB-dependent 
inflammatory genes by influencing the repacking of the uncoiled DNA/chromatin structure. 
This repression process is caused by the deacetylation of NF-κB at multiple levels, including 
its subcellular localization, transcriptional activation, DNA-binding and IκBα assembly (Chen 
and Greene, 2004). The HDACs known to be involved in the modulation of NF-κB 
transcriptional activity are the class I members HDAC1, HDAC2 and HDAC3 (Ashburner, 
Westerheide and Baldwin, 2001, Kiernan et al., 2003). Recent studies have indicated that also 
class III HDAC SIRT1 inhibits NF-κB by affecting the transactivation potential of NF-κB 
subunit (Chen et al., 2005b, Yeung et al., 2004). 
Both of the subunits of the NF-κB heterodimer, p50/p65 are subjected to 
acetylation/deacetylation (Chen et al., 2001, Chen and Greene, 2004). Deacetylation by 
HDAC3 apparently promotes RelA/p65 binding to nuclear IκBα, which in turn leads to 
activation control of NF-κB by influencing the translocation of RelA/p65 from nucleus to the 
cytoplasm (Chen et al., 2001, Kiernan et al., 2003). In contrast, the intranuclear p50 subunit 
has been shown to be complexed with HDAC1 and thus can suppress gene expression by 
inhibiting the NF-κB activation (Zhong et al., 2002). HDAC1 has also been shown to recruit 
the p65 subunit directly (Ashburner, Westerheide and Baldwin, 2001), resulting in repression 
of NF-κB activation. HDACs may also associate with the p50/p50 homodimer, which serves 
mainly as a negative regulator of NF-κB activity through competing with p50/p65 for NF-κB 
response elements on DNA and through its association with the co-repressor histone 
deacetylase. HDAC1 and HDAC2 are also capable of interacting with other co-repressors to 
orchestrate the suppression of gene expression . 
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Corticosteroids, which are widely used anti-inflammatory agents, reverse histone 
acetylation at the site of inflammatory gene transcription, either by direct binding of the 
activated glucocorticoid receptor to NF-κB-associated co-activators or by recruitment of 
histone deacetylases to the activated transcription complex. HDAC2, which can interact with 
the p65 subunit (Rahman, Marwick and Kirkham, 2004), has been shown to be recruited to the 
site of transcription by corticosteroids to switch off the genes which have been activated by 
inflammation (Barnes, 2006).  
 
2.5 Signal integration - the role CBP/p300 
 
All signal transduction pathways are regulated, at some level, by phosphorylation, making 
this covalent modification relevant to most, if not all, areas of cell signaling (reviewed in 
(Pawson and Scott, 2005)). Post-translational phosphorylation is a dynamic, reversible 
regulatory mechanism catalyzed by enzymes that add (kinases) or remove (phosphatases) 
phosphate groups from proteins by acting on amino acid residues, especially on 
serine/threonine or tyrosine. Furthermore, (de)phosphorylation switches "on" or "off" many 
enzymes and receptors involved in signal transduction. Kinases and phosphatases themselves 
may be regulated by phosphorylation and these enzymes are also able to activate many 
substrate molecules, which in turn can lead to amplification of the initial signal. This network 
of pathways usually involves several proteins phosphorylating each other either directly or 
indirectly.  
In addition to acetylation of histones, the intensity and duration of the inflammatory 
response is regulated by phosphorylation, and, sequentially/subsequently by acetylation of 
transcription factors, and non-histone proteins. Though the basic mechanisms of the 
interplay(s) between many inflammatory pathways are yet to be resolved, it has been assumed 
that phosphorylation facilitates these interactions by inducing binding of transcriptional co-
activators, such as histone acetyltransferases (Cheung et al., 2000, Lo et al., 2000). 
One of the key elements controlling the proinflammatory gene transcription is the 
transcriptional co-activator cyclic adenosine monophosphate-response element (CRE)-binding 
protein, and its structural homologue, p300, also known as CBP/p300. This co-activator has 
been shown to possess intrinsic HAT activity and its role in chromatin remodeling has proven 
to be very crucial (Blobel, 2002). Moreover, this protein has an important role in the initiation 
of transcription by RNA polymerase II and the transcriptional activity of inducible 
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transcription factors, including NF-κB, appears to depend on interactions with the CBP/p300 
(Sheppard et al., 1999, Janknecht and Hunter, 1996).  
The role of the physical association of NF-κB subunit RelA/p65 and CBP/p300 for 
proinflammatory gene transcription has been studied in different cell types (Gerritsen et al., 
1997, Shenkar et al., 2001) and it has been shown that phosphorylation of p65 by protein 
kinase A (PKA) stimulates NF-κB-dependent gene expression by enhancing p65 association 
with CBP (Zhong et al., 1997, 1998). Furthermore, this phosphorylation governs the 
recruitment of HAT activity of CBP/p300 by RelA/p65 and thus facilitates the DNA binding 
and full transcriptional activity of NF- κB (Duran et al., 2003, Vermeulen et al., 2003, Zhong 
et al., 2002). Moreover, RelA/p65 activity has been shown to be repressed by histone 
deacetylases 1, 2 and 3, SIRT1 and some corepressors (Ashburner et al., 2001, Chen et al., 
2001, Lee et al., 2000, Yeung et al., 2004). 
Mitogen-activated protein kinases (MAPKs) and phosphatidylinositol 3-kinase (PI-3K) 
cascade pathways have also been shown to contribute to the transmission of extracellular 
inflammatory signals to NF-κB-driven transcription (Rao, 2001, Darieva et al., 2004). 
Although the exact mechanisms of NF-κB activation via these kinases remain to be clarified, it 
has been suggested that the phosphorylation of the transactivation domain of p65 is mediated 
via functional interaction with the transcriptional coactivator CBP/p300 (Madrid et al., 2001, 
Darieva et al., 2004). 
Phosphorylation can be inhibited by chemical compounds that directly inhibit the 
enzymatic activation of some pathway's regulator (Lee et al., 2005, Liang et al., 2005). For 
example, inhibition of PI-3 kinase, a member in one of the major pathways of intracellular 
signal transduction, prevents the phosphorylation and activation of the next kinase 
downstream (AKT, a serine/threonine kinase residing within the cytosol) in its cascade. 
Deactivated AKT in turn effects the phosphorylation status of downstream target molecules 
and in that way modulates the expression of nuclear proteins. (Martin et al., 2003, Strassheim 
et al., 2004) 
Instead of focusing on simply HATs/HDACs and/or phosphorylation governing the activity 
of a single pathway, a number of recent studies have addressed the question of cross-talk 
between acetylation and phosphorylation and subsequent co-regulation of two or more 
signaling routes. (Kouzarides, 2000, Nowak and Corces, 2004). Today there is evidence that 
co-regulation of signaling pathways - such as NF-κB and PI-3K - does indeed exist (Goodman 
and Smolik, 2000, Chen and Greene, 2004, Huang and Chen, 2005). Also, a coupling of 
histone H3 phosphorylation and acetylation has been observed during cytokine-induced gene 
expression mediated by IκB kinase α (Anest et al., 2003) and in response to epidermal growth 
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factor stimulus (Cheung et al., 2000). However, although the interplay between 
phosphorylation and acetylation is well supported by a number of studies, the extent to which 
one is dependent on the other to initiate a full activation of inflammatory genes is still unclear 
(Loury and Sassone-Corsi, 2004, Mahadevan et al., 2004). The concurrent or sequential 
synergistic actions of acetylation and phosphorylation nevertheless greatly expands the 
repertoire of the signaling systems and the absolute requirement for the transcriptional 
coactivators in the actions of many (or even most) transcription factors indicates that they will 
continue to provide a fruitful target for studies aimed at understanding the complex 
interactions that underlie the control of cell growth and differentiation. Thus, it will be no 
surprise if future studies reveal multiple interactions linked to modification of histones and 
transcription factors.  
 
2.6 Regulation of IL-6 and iNOS 
 
Interleukin 6 is a multifunctional, proinflammatory cytokine secreted by macrophages in 
response to infection. Thus, this cytokine can be induced in response to LPS and viral 
infection, and it has been shown that several signaling pathways mediate its expression 
(Matsuda and Hirano, 2000).  The promoter region of IL-6 gene contains three transcription 
start sites (Yasukawa et al., 1987), including  NF-κB -binding site (Libermann and Baltimore, 
1990). Furthermore, IL-6 has been shown to be a target gene for transcription factors such as 
activator protein-1, cAMP response element (CRE)-binding protein (CREB) and nuclear factor 
for IL-6 expression (NF-IL6) (Akira et al., 1990, Alberts et al., 1993, Dendorfer et al., 1994), 
which are capable of interacting with the IL-6 promoter in order to initiate mRNA synthesis.  
In vitro studies with primary human microglia culture, as well as with cultures of murine 
origin, have shown that microglia  express mRNA transcripts of receptor for IL-6 (Sawada et 
al., 1993, Lee et al., 2002).  Moreover, very recently both the transcriptional and protein level 
of IL-6 have been shown to be upregulated in microglial cells in response to LPS under in 
vitro and in vivo conditions (Lund et al., 2006). The activation program of signaling cascades 
that eventually lead to expression of IL-6 includes intracellular cross-talking signal 
transduction pathways MAPK, NF-κB, and Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathways. 
 
 
 
 39
The action of IL-6 is initiated by binding to its functional receptor complex that is 
composed of two subunits, the IL-6 binding protein and a transmembrane signal transducing 
glycoprotein (gp130) (Taga et al., 1989). Though the gp130 has no binding capability by itself, 
it associates with the IL-6/IL-6R complex and allows the activation of signal transduction 
(Murakami et al., 1993). The next activation step involves phosphorylation of the members of 
the JAK family, followed by phosphorylation of STAT(3), which is a transcription factor 
mediating  the cellular response to IL-6 (Akira S et al., 1994, Zhong et al., 1994). Furthermore, 
upon dimerization of the IL-6 receptor complex, hyperphosphorylation of  MAPK and 
upregulation of its kinase activity, leading to induction of the cascade, has also been observed 
(Daeipour et al., 1993). As a summary, the key events in the regulation of IL-6 are the 
phosphorylation steps of different signaling pathways. 
Nitric oxide (NO) is a free radical that is synthesized by nitric oxide synthases from the 
amino acid L-arginine and oxygen (Moncada et al., 1989). As a signaling molecule, NO is 
unusual since it has no cell surface receptor. The inducible isoform of nitric-oxide synthase 
(iNOS), which catalyzes the oxidation of one of the equivalent guanidinium nitrogens of 
arginine to form NO and citrulline (Stuehr, 1996), is widely expressed by microglia (Zielasek 
et al., 1992). iNOS regulates the level of NO production primarily at the transcriptional level 
via NF-κB and AP-1 (Chartrain et al., 1994). The promoter region of iNOS gene contains 
oligonucleotide motifs for the binding of several cytokine-induced, as well as LPS-induced, 
transcription factors (Lowenstein et al., 1993), and thus the silent gene is capable of 
responding to bacterial stimuli. The LPS induced induction of iNOS expression has been 
shown to involve some of the same pathways involved in the regulation of IL-6. Namely, the 
aforementioned signaling molecules like  JAK/STAT proteins, NF-κB/IκB pathway as well as 
MAPK have been shown to be targeted by NO. For example, NO is known to inhibit the DNA 
binding activity of NF-κB (Matthews et al., 1996, Moorman et al., 1996). There is also 
experimental support from knockout mice studies, that the activation of both STAT3 and NF-
κB are iNOS dependent (Hieholzer et al., 1998). Furthermore, NO is also known to affect the 
production of several cytokines, including IL-6 (Bogdan, 2000). All these findings support the 
argument that the signaling between inflammatory cells and NO is mainly indirect through 
iNOS derived NO. 
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2.7 In vitro models of brain inflammation 
Background 
Though rapidly expanding, our understanding of the biochemical processes involved in 
inflammation is still limited. Since an invasive approach to study these interactions with 
human subjects is not possible, most of our knowledge has been gained through application of 
basic research methods. Over the years, in vitro systems have proven to be well suited for 
studying the multitude of biological processes in a more isolated context.  They have been 
successfully used to elucidate mechanisms of brain inflammation, such as the involvement of 
different signaling pathways (van Noort, 2006). Many target cells of inflammation have been 
identified and the intricate cellular changes induced by inflammatory stimuli have been 
delineated. For example, in vitro systems have been useful for understanding the effects of 
certain structurally defined compounds and the mechanisms of inflammation, for which target 
cells and the biochemical processes involved in the inflammation are well known. The 
physicochemical environment of cells is easily controlled in vitro. Culture conditions can be 
manipulated by adding or removing substances from the culture medium, permitting precise 
analysis of sequences of events. The concentrations of the different test chemicals can be 
controlled in terms of the amount being delivered to the entire cell population or to an 
individual tissue slice. 
By using in vitro systems it is possible to study separate areas of the nervous system 
isolated from normal in vivo homeostatic environments and mechanisms. The use of in vitro 
techniques allows for exact and highly specific measurement of many fundamental biological 
processes, such as production or secretion of inflammatory cytokines, chemokines etc. Since 
they represent a defined and controlled system, in vitro techniques offer many advantages in 
characterising multiple inflammatory mechanisms; but one should never overlook the fact that 
they are an artificial system. The in vitro cell culture systems are limited in that they represent 
tissues or cells taken out of the body. They may not behave normally when removed from the 
blood, immune system, nervous system or neighbouring tissues that help make them what they 
are. Therefore,  in vitro tests hold their greatest potential in providing information on basic 
biological processes. This information may also be useful in refining specific experimental 
questions to be addressed in the whole animal but effects seen in vitro invariably have to be 
confirmed or substantiated in vivo. In addition, one must bear in mind that the multiple 
functions of individual immune cells and the overall complexity of the nervous system lead to 
the fact that it becomes very difficult to define how well any single in vitro system replicates 
the in vivo system.  
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Various types of in vitro approaches, including culturing of different cell lines, primary cell 
cultures and slice cultures, have been applied to produce data for evaluating potential and 
known inflammatory substances that affect the brain (van Noort, 2006). The use of animal - 
including human - cell culture methods has expanded enormously during the last 25 years, 
with new applications and revised methods appearing all the time. 
 
Cell lines 
A neural cell line may be obtained from the primary culture (see later paragraphs) by 
enzymatically detaching the cultured cell layers. This subcultivation process is repeated 
normally every three to four days, and after several steps, the cell line is established. 
Established (also referred to as continuous) cell lines can be obtained from donors of various 
ages and are comprised of a single cell type. In culture, these types of cells can be serially 
propagated for a limited number of cell divisions. If the cell line has transformed into tumour 
cells, it can be propagated indefinitely. Transformed tumour cell lines are often derived from 
actual clinical tumours, but it is also possible to induce transformation by chemical or viral 
treatments.  Immortalized cell lines are also generated from established cell lines with limited 
life span that undergo crisis after which their growth potential changes and the life span 
become unlimited.  
Clonal cultures are derived from the progeny of a single cell, either from established or 
transformed cultures. Once the cell line phenotype is established, it does not change; however, 
with increasing passages it slowly drifts with regard to its physiological responsiveness 
(Banker and Goslin, 1998) 
The major advantage of using cell lines is the consistency and reproducibility of the results 
that can be obtained from using a batch of clonal cells (Freshney, 2000). If one wishes to study 
inflammation, then cell lines provide a way to learn how cells regulate certain mediatory 
processes such as signaling and transcription. This method also allows for new drug target 
identification and provides researchers an easy access to a source of unlimited numbers of 
cells from one individual that are all genetically identical. 
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Primary cell cultures 
Primary cultures, which are obtained directly from the nervous tissue of an animal can 
maintain their differentiated state for a short period (days to weeks). Functionally 
differentiated primary cell cultures have a limited life span, and although maintenance of the 
differentiated properties can be improved by additives to the culture medium or components of 
the extracellular matrix, cell specific functions will eventually decline.  
In primary cultures the initial cell population is extremely heterogeneous, and it is 
impossible to obtain a group of cells in culture that is completely representative of those in 
vivo. For some specific questions it may be desirable to have cultures of only one cell type, 
such as astrocytes or microglia. These cultures can be obtained from distinct brain regions by 
selection of donor optimal age. Once growing in culture, the cell type of interest can be 
selected by a variety of methods. (Banker and Goslin, 1998) 
The benefit of primary cultures is that the cells have not been "modified" in any way (other 
than enzymatic or physical dissociation). Similarly to cell lines, primary cultures can be used 
to test the effect of various chemical compounds or drugs on specific cell types. The ability to 
provide a cell type-enriched culture offers a primary advantage over dissociated cell cultures, 
i.e. the possibility to make biochemical measurements on large numbers of cells rather than on 
a single cell. 
The disadvantage of primary cultures is that, after a period of continuous growth, the cell 
characteristics can change and may become quite different from those found in the starting 
population (Freshney, 2000). Cells can also adapt to different culture environments (e.g. 
different nutrients, temperatures, salt concentrations etc.) by varying the activities of their 
enzymes. The mixed nature of each preparation, the limited lifespan of the culture and 
potential contamination problems are some of the other disadvantages associated with using 
primary cultures.  
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Co-cultures 
Mixtures of two or more different kinds of cell types that are grown together are referred to 
as co-cultures. Co-cultures are used to study the interactions of different cell types and the 
utility of these systems has been well documented in the literature. One of the major 
advantages of co-culture system is the ability to investigate the molecular changes that occur 
as a result of cell-cell  interactions (Freshney, 2000). For example, direct cell-cell contacts can 
be avoided by culturing two different cell types in different compartments of a culture well. In 
this kind of system, cells are grown on separate permeable supports but in the same culture 
medium interface, allowing study of functions such as transport and secretion. Although the 
"cross-talk" between cell types might be bidirectional and different from in vivo, this system 
provides extra information when cell based assays are applied. Similar to cell lines and 
primary cultures, co-cultures can also be easily manipulated by adding the compounds of 
interest into the culture medium.  Modern assay techniques provide the ability to determine 
how potential compounds affect cell proliferation, cytokine production, cellular responses and 
to interpret and predict many biological properties of potential drug compounds. 
 
Tissue slices 
Slice cultures are normally prepared from infant animals. In these cultures, the age of the 
donor is a critical parameter determining the degree of organotypic organization achieved in 
the final preparation. Usually, tissue is obtained from rodents within the first week of life. By 
that time, a fair degree of tissue-specific cytoarchitecture has already been established and the 
peak of neuronal migration has passed. Within 2 to 3 weeks in culture, an original slice will 
thin to form a pseudomonolayer of cells and the degree of maturation and differentiation can 
be determined prior to the experimental manipulation. For ex vivo -studies, tissue can be 
obtained from any age of the animal; however, the maturation of the region of interest prior to 
sampling and interpretation of data must be considered. (Banker and Goslin, 1998). 
Slice cultures prepared from the hippocampal region are perhaps the most widely used in 
vitro -method of organotypic tissue culture (Figure 5.). Although the hippocampus has 
significant longitudinal connections and inputs from various areas of the brain, which are 
disrupted during the transverse sectioning, the resulting slices still possess a complex laminar 
circuitry that remains functional during the culture time (Freshney, 2000). When compared to 
cell lines and co-cultures, this phenomenon provides possibility of studying cellular 
interactions in living tissue. 
 
 44
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. culture   
well 
2. culture 
medium 
1. hippocampus     
slice 
Figure 5. 
 
A schematic drawing showing the principle of the organotypic slice culture system 
using the so called interface method; 
1. Hippocampus slice is placed on a membrane of a culture insert. 
2. Culture medium is added into the culture well to reach the level of the insert 
membrane. 
3. Insert is placed inside the well. 
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3. AIMS OF THE STUDY 
 
Inflammation in the brain attracts an unremitting stream of immune cells towards the 
injured area. To lessen the direct and/or bystander damage, microglia cells appear to pave the 
way for repair by releasing a complex array of chemicals and subsequently converting 
themselves into phagocytic macrophages that engulf dead cells. On the other hand, it seems 
that excessive inflammation can lead to a sequence of events where overactivated microglia 
become cytotoxic and thus worsen the outcome of inflammatory response. 
The intracellular innate immune response involves post-translational modification of 
histones and transcription factors by histone acetylases and deacetylases. Since HDACs have 
been identified as playing a key role in the regulation of not only a number of inflammatory 
related diseases but also cancer, controlling the activity of these enzymes with specific 
inhibitors has fascinated scientists working in the field of drug development. 
Different in vitro brain slice techniques have been introduced as representing 
"intermediate" models between cell cultures and in vivo -models to help to disentangle the 
complexity of neuroinflammation, but the efficacy of these models has seldom been reported. 
Against this background we wanted to explore whether the extent of the inflammatory 
response could be affected by HDACs in different neural inflammation models. Moreover, we 
wanted to gain a better insight into the applicability of using the slice culture model in 
inflammation studies. 
 
The specific aims were: 
 
1. To refine and characterize the organotypic hippocampal slice culture model to suit 
 the needs of neuroinflammation studies, and furthermore, to use the model together 
 with other cell culture methods to study the impact of pro- and anti-inflammatory 
 compounds, especially histone deacetylase inhibitors. 
 
2. To investigate the effects of histone deacetylase inhibitors on inflammatory 
 responses of  microglia cells using the models mentioned above. 
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4. MATERIAL AND METHODS 
4.1 Animals 
The primary astrocytes and microglial cells used in Studies II and III were isolated from 1- 
to 2-day-old Wistar rat pups. Hippocampal cells used in Study II were isolated from 17-day-
old Wistar rat embryos. Cerebellar granule cells were isolated from the cerebella of 7-day-old 
Wistar rats and postnatal day 7-8 (P7-P8) Wistar rat pups for organotypic slice cultures were 
used in Studies I-IV. All the animals were obtained from National Laboratory Animal Center 
(NLAC),  University of Kuopio, Finland. The studies were conducted according to the Council 
of Europe (Directive 86/609) and Finnish guidelines, and approved by the State Provincial 
Office of Eastern Finland. 
 
4.2 Chemicals 
To induce inflammation in Study I, the hippocampal slices were exposed to 
lipopolysaccharide (LPS from E. coli 055:B5, L6529, Sigma, St Louis, USA). To test whether 
the slices would respond to regulators of inflammation, a pro-inflammatory stimulus together 
with LPS was introduced by using a histone deacetylase inhibitor trichostatin A (Sigma, St 
Louis, USA ). To test the response of an anti-inflammatory stimuli, we used helenalin 
(BIOMOL Research Laboratories, Plymouth Meeting, PA, USA), a known NF-κB inhibitor. 
In addition to LPS and TSA, HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, 
Alexis Biochemicals, Lausen, Switzerland) and 4-dimethylamino-N-(6-hydroxycarbamoyl-
hexyl)-benzamide (M344, Alexis Biochemicals, Lausen, Switzerland) were used as 
proinflammatory stimuli in Study II and in addition to helenalin, another NF-κB inhibitor, 
caffeic acid phenethyl ester (CAPE, Sigma, St Louis, USA) was used. Pro- and anti-
inflammatory compounds were tested in different cell and slice culture models. 
In Study III we expanded our inflammation research and tested whether different short-
chain fatty acids (SCFAs, purchased from Sigma), especially sodium butyrate, could regulate 
the inflammatory responses in different neural models. The involvement of protein acetylation 
and NF- κB binding activities were also studied. 
Study IV supplemented the previous studies, a number of different Toll-receptor ligands 
and different inhibitors of signaling pathways together with TSA, okadaic acid and/or 
LPS/LPS Ultra Pure treatments were analyzed using N9 cell line and hippocampal slices. 
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Table 1. Summary of the compounds and their properties used in Studies I-IV. (For 
references, see text). 
 
     Compound     Property Study I Study II Study III Study IV 
TSA  HDACi x x  x 
SAHA HDACi  x   
M344 HDACi  x   
Helenalin NF-κB inhibitor x x   
CAPE NF-κB inhibitor  x   
Butyrate SCFA, HDACi    x  
Dexamethasone 
Glucocorticoid, 
immunosuppress
ant 
   x 
Valproate SCFA   x  
Propionate SCFA   x  
Valerate SCFA   x  
Caproate SCFA   x  
LY294002 PI3K inhibitor    x 
Wortmannin PI3K inhibitor    x 
Pam3CSK4 TLR2 ligand    x 
SLTA TLR2 ligand    x 
Zymosan TLR2 ligand    x 
Flagellin TLR5 ligand    x 
ODN1826 TLR9 ligand    x 
IKK-2 IV 
inhibitor of IKK-
2 in  NF-κB 
signaling 
   x 
LPS 
(E.coli 055:B5)
endotoxin, 
induces 
inflammation, 
TLR2 and TLR4 
ligand 
x x x x 
Ultra Pure LPS         
(E. coli 0111:B4)
purified LPS, 
TLR4 ligand 
   x 
Okadaic acid inhibitor of PP1 
and PP2A 
   x 
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4.3 Cell culture 
 
Murine N9 microglia 
The murine N9 microglial cell line was kindly provided by Dr. Paola Ricciardi-Castagnoli 
(University of Milano-Bicocca, Milan, Italy). N9 cells were cultured in Iscove’s Modified 
Dulbecco’s Medium (Gibco) with 5% heat-inactivated fetal bovine serum (Gibco) on Nunc 
(Nalgene) dishes and 12-well clusters.  
 
Rat primary astrocytes 
Primary astrocytes were isolated from 1- to 2-day old Wistar rat as described earlier by 
Kerokoski et al. (2001). The cerebral cortices and midbrain were excised and the tissue 
without meninges and blood vessels was minced into small pieces. Cells were separated by 
trypsinization (0.025 % trypsin, 15 min, 37°C). After centrifugation and trituration, the tissue 
was filtered through 230 µm strainer. The cells were cultured in tissue culture flask in 
Dulbecco's modified eagle media (DMEM, Sigma) supplemented with 10 % heat-inactivated 
FBS, 2 mM glutamine (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). 
Flasks for pure astrocyte cultures were shaken vigorously before each medium change, which 
was done first after two days and then after every four days. The astrocytes were detached by 
trypsinization after the culture bottles were confluent and used for both astrocyte and co-
cultures.  
 
Rat primary microglia 
Primary microglial cells were isolated in the same way as astrocytes and they matured on 
the top of astrocytes. The culture flasks were not shaken until two weeks after the isolation, 
when the floating microglia were harvested from confluent astroglial layers by rotating the 
flasks on an orbital shaker for a few hours. Microglia were harvested from the same flasks 4-5 
times every seventh day. After 1-2 hours of plating, the medium was changed to remove 
nonadherent cells. Cells were used for co-culture or pure microglia culture. Experiments were 
initiated 24 h after plating. The purity of the microglial cultures (over 95 %) was confirmed 
using antisera to CD11b (OX-42, Serotec, Oxford, UK). 
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Rat hippocampal cells 
Hippocampal cells were isolated from 17-day-old Wistar rat embryos and cultured as 
described by Brewer et al. (1993). After preparing the hippocampus from embryonic brain, the 
cells were separated by papain treatment (0.5 mg/mL, 10 min, 37°C) followed by 
centrifugation and trituration. The cells were plated onto poly-D-lysine-coated (Sigma) plates 
in Neurobasal medium (Gibco) supplemented with 0.5 mM glutamine, 100 U/mL penicillin, 
100 µg/mL streptomycin and 5% inactivated FBS. On the following day, the FBS-containing 
medium was substituted with B27-supplemented (Gibco) medium. 
 
Rat cerebellar granule cells 
Cerebellar granule cells were isolated from the cerebella of 7-day-old Wistar rats and 
cultured as described by Schousboe et al. (1989). After dissecting the cerebella out of the 
brains, the cells were separated by trypsin treatment (0.025 % trypsin, 15 min, 37°C) followed 
by centrifugation and trituration. The cells were plated onto poly-D-lysine-coated (Sigma) 
plates in the DMEM media supplemented with 10 % heat-inactivated FBS, 2 mM glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin and 25 mM potassium chloride (KCl). After 
two days in culture, the medium was supplemented with 10 µM 1-β-D-cytosine-
arabinofuranoside (Ara-C, Sigma). 
 
4.4 Co-cultures 
In Study II, the hippocampal cells, the astrocytes  and the microglial cells were co-cultured 
in Neurobasal medium using 24-well plates. Astrocytes were added four days after isolation 
and culturing of hippocampal cells. Microglia were added 3 days after the astrocyte-
hippocampal culture. The co-cultures were developed 24 hours before experiments were 
initiated.  
In Study III, we used a co-culture of cerebellar cells,  astrocytes and microglial cells. 
Similarly as in Study II, astrocytes were added 4 days after isolation of cerebellar cells. 
Microglia were added 3 days after astrocytes and the experiments were initiated 24 h after 
addition of microglia. DMEM media supplemented with 10 % heat-inactivated dialysed FBS 
(Sigma), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin and 25 mM KCl 
without Ara-C was used as culture media and the cells were plated onto 24-well plates. 
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4.5 Slice culture 
Organotypically cultured hippocampal slices used in Studies I-IV were isolated from P7-P8 
rats and prepared using the modified interface culture method described by Stoppini et al., 
1991. Wistar  pups were decapitated, and the brains were rapidly dissected and placed in a 
petri dish in ice-cold 1x Dulbecco's Phosphate Buffered Saline (DPBS) without calcium and 
magnesium (Biowhittaker™, Belgium). The hippocampi of both sides were isolated and 
sectioned into 400-µm transverse slices with a McIlwain tissue chopper (Mickle Laboratory 
Engineering Co. Ltd, Goose Green, UK). The slices were then carefully separated and 
transferred on to porous membrane inserts (one slice per insert) of 12-well culture plates 
(Transwell TR 3462; Costar, Corning, NY, USA). To reach the level of insert membrane, 
some 600 µL culture medium, consisting of Neurobasal medium with 1x B27-supplement 
(from Gibco), 1 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin, was 
added to the lower compartment of each well and the culture plates were then placed in a 37°C 
humified incubator enriched with 5% CO2. On the first day of culture, inactivated fetal bovine 
serum (Hyclone) was added to the culture medium at a concentration of 10%. On the next day, 
the culture medium was replaced with fresh medium without serum and from that time serum-
free media was changed twice a week. 
 
 
Table 2. Summary of the different culture methods applied in each study 
 
     Method Study I Study II Study III Study IV 
Slice culture     x     x     x     x 
Primary microglia      x     x  
Primary astrocytess      x     x  
Primary hippocampal 
cells 
     x   
Murine N9 microglia      x     x     x 
Cerebellar granule cells       x  
Co-cultures      x     x  
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4.6 Characterization of hippocampal slice culture model 
 
Monitoring biochemical recovery and responses 
First, some hippocampal slices were cultured for 7 days in vitro (7 DIV) and the culture 
medium was collected at 24h intervals during the culture period. LDH leakage to the culture 
medium was measured with a CytoTox 96 nonradioactive cytotoxicity assay kit obtained from 
Promega (Madison, WI, USA) and the nitrite concentration in the medium was measured by 
the Griess reaction. The concentrations of cytokines IL-6 and tumour necrosis factor (TNF)-α 
released into the medium were measured by an ELISA using OptEIATM kits or sets obtained 
from Pharmingen (BD Biosciences, San Diego, CA, USA).  
Subsequently, samples of culture medium were collected at appropriate time points to 
further monitor the biochemical status of cultures at the one month time period.  
 
Monitoring morphological recovery and responses 
In Study I, some hippocampi were also rapidly sliced at 400 µm and immediately fixed 
with 4% paraformaldehyde for 1-2 h and rinsed three times with 0.05 M TBS-T, pH 7.6 (Tris-
buffered saline + 0.1% Triton X-100) prior to staining to reveal the morphological status at the 
beginning of the culture. For microglia, hippocampal slices were stained with Alexa Fluor 488 
conjugated fluorescent Griffonia simplicifolia isolectin IB4 (Molecular Probes, Eugene, OR). 
IB4 was applied at a concentration of 0.5 µg/ml in TBS-T and slices were incubated overnight 
at 4°C on a shaker. Before visualization, samples were rinsed with 0.1 M phosphate buffer and 
mounted on slides. We also performed immunocytochemical staining with a microglia marker 
OX-42, an antibody that recognizes type 3 complement receptors CR3 on mononuclear 
phagocytes. Primary antibody was diluted 1:20 000 with 0.05 M TBS-T, pH 7.6, slices were 
incubated for 1 week at 4°C on a shaker, rinsed thoroughly, followed by overnight incubation 
(4°C) with biotinylated secondary Ab (sheep anti-mouse, 1:1000, Serotec) and 2h incubation 
(room temperature) with avidin peroxidase (1:1000 ExtrAvidin E-2886, Sigma). The 
immunoreactive product was visualised with 3,3'-diaminobenzidine tetrahydrochloride 
dihydrate (DAB, 0.5 mg/ml, Sigma) in a nickel solution containing hydrogen peroxidase (25 
µg/ml). 
For epifluorescence immunodetection, primary antibodies to glial fibrillary acidic protein 
for astrocytes (GFAP: dilution 1:10 000; DAKO, Denmark) and doublecortin for neurons 
(DCX C-18: dilution 1:2500; Santa Cruz Laboratories, Santa Cruz, CA, USA) were used. 
After an overnight incubation with primary antibody at 4°C and thorough rinsing, 1:1000 
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diluted goat anti-rabbit Alexa Fluor 488 secondary antibody  (Molecular Probes) to GFAP and 
1:500 diluted biotinylated rabbit anti-goat secondary (Vector BA-5000; Burlingame, CA, 
USA) followed by tertiary antibody (goat anti-rabbit Alexa Fluor 488; 1:1000 dilution) to 
DCX were applied, respectively, also overnight at 4°C. All the antibodies were diluted with 
0.05 M TBS-T, pH 7.6.  
Subsequently, samples of slices were collected and stained at appropriate time points to 
further monitor the morphological status of cultures at the one month time period. To visualize 
the morphological integrity and both dead or dying cells and living cells, we used standard 
Nissl staining and the Live/dead-cytotoxicity kit (L-3224, Molecular Probes), respectively, 
according to the manufacturer's protocol. 
 
4.7 Microscopy  
Pictures from stained slices were taken with an Olympus DP50 microscope digital camera 
system connected to an Olympus BX40 microscope (Olympus Optical Co, Ltd, Japan) with 
appropriate filters. Except for adjustment to the contrast and brightness levels, no other 
manipulations were done to any of the images. 
The purity of the cultures was checked with a Nikon Eclipse TE 300 Inverted microscope 
(Nikon Co, Tokyo, Japan) 
 
4.8 Molecular biology  
Electrophoretic mobility shift assays (EMSA) in Studies II and III were performed as 
described earlier in detail by Helenius et al. (1996). Protein-DNA binding assays were done 
with 5 µg nuclear protein. Double-stranded consensus and mutated oligonucleotides for 
activator protein (AP)-1 (Study II) and NF-κB binding sites (Studies II and III) were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Radioactive bands were visualized with a 
Storm 860 PhosphorImager and pixel volumes of specific bands were calculated with 
ImageQuaNT 4.2a software (Molecular Dynamics). 
For Northern blot analysis (Study II), some 4 µg of total RNA was isolated using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Gene-
specific fragments for riboprobes were generated by PCR, cloned into pGEM-T Easy vector 
(Promega, Madison, WI, USA) and verified by sequencing. After hybridization, the 
membranes with the 32P-labelled riboprobes (generated with the Strip-EZ kit, Ambion, Austin, 
TX, USA) were rinsed and the signals visualized with the Storm 860 PhosphorImager. Filters 
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were reprobed with 32P-labelled 18S riboprobe in the presence of cold 18S in vitro transcripts 
and pixel volumes of specific bands were calculated with ImageQuaNT 4.2a software. For 
normalization and standardization, the intensities of specific bands were divided by the 
intensities of the 18S bands corresponding lanes. 
The N9 microglial cells in Study IV were transfected with pTAL-Luc and pNFκB-Luc 
Vectors from Clontech Lab (BD Biosciences, Palo Alto, USA). pNFκB-Luc is a reporter 
vector designed for monitoring the activation of NF-kB signaling pathway. The pTAL-Luc 
vector served as a negative control for the background. For transfection, the recommended 
protocol (Roche, Penzberg, Germany) and FuGENE™ 6 Transfection Reagent was used. In 
brief, transfection with pTAL-Luc and pNFκB-Luc vectors (0.6 µg/ml) was done for 12h in 
culture medium after which LPS and drugs were added for 24h. Luciferase activity of the cells 
was assayed with Luciferase kit from Promega (Madison, USA).   
 
4.10 Statistics  
In Studies I-IV, the statistical analyses were conducted with SPSS software (program 
version 11.5.1 for Windows, SPSS Inc., Chicago, IL). The differences between control and 
treated groups were analyzed using non-parametric, 2-independent samples Mann-Whitney U-
test with the p-values of 0.001, 0.01 and 0.05 as thresholds. All values are expressed as means 
± SD. 
 
Estimation of optimal sample size for slice cultures 
To determine the minimum number of animals, yet appropriate sample sizes for slice 
culture experiments, we undertook power analysis calculations. First, based on our previous 
results, we estimated the effect size among different experimental units.  Thereafter, the 
sample size was set to six per group and the significance level to 5% to determine the effect on 
statistical power. In order to reduce the within-group variation, we used a lognormal 
distribution and carried out the statistical power analysis calculations using nQuery Advisor® , 
version 5.0, (Statistical Solutions, Saugus, MA) computer program for Wilcoxon (Mann-
Whitney) rank-sum test. 
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5. RESULTS 
 
5.1 Characteristics of  hippocampal slice culture model 
Organotypic slice cultures from different brain regions have been introduced as an 
"intermediate" model between cell lines and in vivo models. One of the purposes of Study I 
was to gain insight into the behaviour of hippocampus tissue slices in refined, serum-free 
culture protocol. 
 
Biochemical changes after explantation 
The isolation procedure of rat hippocampal slices from postnatal brain causes trauma and 
acute inflammatory reaction due to removal of afferents and efferents and the transversal 
slicing of hippocampus.  
In order to characterize how well the slices had recovered from the isolation, we collected 
the culture medium after every 24 h during the 7 DIV culture period and measured the 
secretion of IL-6, TNF-α and LDH leakage. The secreted level of IL-6 was highest at 48 h 
after explantation and returned to the basal level by 4 DIV. The peak levels of LDH and TNF-
α were recorded at 1 DIV and reverted to control levels by 3 DIV. From that time, the levels of 
cytokines and LDH exhibited some variability but remained at rather low levels, implying that 
after 4-5 days of culture the hippocampal slices had largely recovered from the explantation 
procedure as assessed  by these biochemical assays. (Study I, fig.1) 
 
Morphological changes during culture period 
Immediately after sectioning, microglia displayed an idiotypical "resting", ramified 
morphology with small cell bodies and numerous branching processes (Study I, fig. 7A). After 
1 DIV, the microglia  started to revert gradually into an intermediate, "reactive" form with 
larger cell bodies and several thicker branches (Study I, fig. 7B) and by 4-5 DIV a number of 
the IB4-positive cells appeared with their characteristic rounded, "amoeboid" phenotype, 
though also pleomorphic cells exhibiting projections were visible (Study I, fig. 7C-D). As the 
culture time extended, the morphological  polymorphism of the microglial-cell population 
continued, e.g., all shapes of microglia from "amoeboid" like to "resting", ramified  were 
found in all of the IB4 labeled slices. The same phenomenon was seen when the slices were 
stained with OX-42 (Study I, fig. 8). 
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GFAP staining revealed the characteristic star-shaped morphology of astrocytes 
immediately after the explantation. In addition, the expansions of astrocytic processes, the 
"end-feet", enveloping the microvessels were clearly visible. (Study I, fig. 9A). After 2 DIV, 
GFAP-positive cells started to transform into fibrous cells with long processes (Study I, fig. 
9B), eventually extending throughout the whole slice by 7 DIV. 
 The dentate area remained prominently covered with cells expressing doublecortin, 
showing the typical morphology of neurons (Study I, fig. 11A and B; inserts). DCX-positive 
cells were found, though in lesser numbers, also in the CA-areas. 
 
5.2  Inflammatory responses in different culture models 
LPS, the bacterial endotoxin, is a well characterized inducer of inflammation. We examined 
the basic inflammatory responses in our different models to determine which would best suit 
our purpose in the subsequent  studies in which we wanted to regulate these responses. 
 
Effect of LPS induced inflammation on slice cultures  
To investigate whether the concentration of  LPS had any effect on the slices during the 24h 
exposure, we pre-exposed the cultures to 0.1, 0.5, 1, 5 and 10 µg/ml of LPS at day 4. The LDH 
leakage did not differ significantly at any of these LPS-concentration levels and the control 
slices showed only a minimally lower level of LDH than the LPS treated slices (Study I, fig. 
3A). The NO and IL-6 levels were clearly higher compared to control slices but LPS did not 
induce any prominent concentration-dependent effect in any treatment group (Study I, fig. 3B-
C).  
To address the question of whether the slice cultures would respond to LPS differently 
during the culture time, we added LPS to the medium at days 7, 14 and 21 in vitro. LPS 
evoked extensive secretion of IL-6 at all of the time points (Study I, fig. 4) in a similar manner 
as at 4 DIV (Study I, fig. 3C).  
We also determined the temporal profile of LPS response by measuring the levels of IL-6, 
TNF-α, NO and LDH at different time points both at DIV 4 and 7. The secreted level of IL-6 
was clearly increased after 6 hours and the highest levels were found after 48 hours both at 4 
DIV and  7 DIV (Study I, fig. 5A). TNF-α secretion was already prominently elevated at 3 
hours and was highest after 12 hours of exposure at 4 DIV. The pattern of TNF-α secretion at 
7 DIV was similar to that seen at 4 DIV, but the overall levels were significantly lower and the 
value after 48 hours was higher than the value at 24 hour exposure time point. (Study I, fig. 
5B). The NO levels at 7 DIV increased by degrees at the different time points but at 4 DIV 
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ascended more evenly (Study I, fig. 5D). The effect of LPS on LDH leakage was highest after 
12 hours both at 4 and 7 DIV. The levels of LDH at 7 DIV were higher than the 4 DIV levels, 
but the overall values at both days remained rather low (Study I, fig. 5C). The DNA-binding 
activity of nuclear NF-kB complex was increased by LPS treatment (Study III, fig. 8). 
 
Effect of LPS induced inflammation on cell culture models 
Generally, in primary microglia, co-cultures and N9 cells, LPS induced a prominent, time 
and concentration dependent secretion of IL-6, TNF-α and NO (see e.g. Study II, fig.1-3) . It 
also upregulated the DNA-binding activity of the NF-kB complex in N9 nuclear extract (Study 
II, fig. 7-8 and Study III, fig. 4). 
LPS treatment also induced AP-1 binding activity but to a lesser extent than that of NF-kB 
binding (Study II, fig. 9 and Study IV, fig. 5). Moreover, the effect of LPS could be detected 
also at the  RNA level i.e. elevation of the levels of IL-6 and inducible nitric oxide (iNOS) 
mRNA expression (Study II, fig. 6) 
 
5.3 Modulation of inflammatory responses 
Acetylation and phosphorylation of proteins have been shown to diversely alter 
inflammatory responses. We wanted to elucidate whether different agonists and antagonists 
would affect the extent of LPS induced inflammation in different neural inflammation models. 
 
HDAC inhibitors 
Histone deacetylase inhibitors are recognized as inducers of protein hyperacetylation. We 
examined the effect of well-known HDACi against LPS induced inflammation and whether 
neurone-glia interactions were involved in this scheme. 
Trichostatin A , a potent, reversible inhibitor of histone deacetylase, potentiated the LPS 
induced inflammatory response time dependently in N9 cells. This potentiation increased 
exponentially from 12 h to 24 h (Study II, fig. 1 and Study IV, fig. 2). These results indicated 
that the proinflammatory response to TSA was a late rather than an early event. 
Similarly, a  clear potentiation was observed in primary microglia (Study II, fig. 2), neural 
co-cultures (Study II, fig. 3A) and slice cultures (Study II, fig. 4, Study I, fig. 6A), 
demonstrating that the effect of TSA was not restricted to transformed N9 cells and that 
neurone-glia interactions did not significantly affect this response. 
 TSA also enhanced the expression levels of iNOS and IL-6 mRNAs of LPS-stimulated N9 
microglia, but alone did not affect the expression levels of these cells (Study II, fig. 6). Also 
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the DNA binding activity of the NF- κB complex was not enhanced by TSA treatment (Study 
II, fig. 7-9). 
 Two other inhibitors of HDACs, SAHA and M344, were also able to induce pro-
inflammatory potentiation of LPS-stimulated secretion of IL-6 and NO, but their effective 
concentrations were at the micromolar level (Study II, fig. 5.) 
 
OKA 
Okadaic acid, a naturally occurring polyether toxin, stimulates intracellular phosphorylation 
and protein translocation. It selectively inhibits protein phosphatases PP2A and PP1 and its 
hydrophobic backbone enables it to enter cells, thus making it a useful tool to study cellular 
processes that are regulated by phosphorylation (Shanley et al., 2001). 
When we compared the okadaic acid and TSA induced proinflammatory responses we 
observed that OKA potentiated the LPS-induced IL-6 secretion in N9 cells already after 6 
hours (Study IV, fig. 2), indicating that the response obtained via phosphorylation mediated 
signaling pathway was faster than that via acetylation mediated pathway.  
Okadaic acid also potentiated the LPS induced IL-6 secretion in hippocampal slice cultures. 
In contrast to TSA treatment, the secretion of NO in N9 cells was clearly downregulated by 
okadaic acid treatment together with LPS exposure when compared to LPS alone but this 
downregulation could not be observed in slice cultures (Study IV, Fig. 2 b and supplementary 
material 1.).  
Altogether these observations demonstrate that the signaling mechanisms behind 
hyperacetylation and hyperphosphorylation are different. 
 
SCFAs 
The anti-inflammatory effect of short-chain fatty acids, especially butyrate, have been 
suggested to be mediated via suppression of NF-kB activation. On the other hand, SCFAs 
have the ability to function as HDAC inhibitors.  
When we examined the role of butyrate in our models, we observed that pretreatment with 
sodium butyrate induced a significant protection against LPS-induced inflammatory response 
in rat primary microglial cells and in co-cultures (Study III, fig. 5A and fig. 6).  Instead, 
transformed N9 cells responded to butyrate treatment in exactly the opposite way. Whether 
exposed simultaneously to LPS or pretreated, butyrate potentiated the cytokine and nitric 
oxide secretion of these cells (Study III, fig. 1). Moreover, both its anti- and pro-inflammatory 
effects were concentration dependent.  
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Irrespective of whether hippocampal slice cultures were exposed to butyrate, either 
simultaneously with LPS or in pretreatment, the concentration of butyrate had a clear effect on 
the secreted levels of IL-6, NO and LDH leakage (Study III, fig. 7A). At the 5 mM 
concentration level, butyrate was clearly anti-inflammatory as judged by the expression of IL-
6. 
This diversity in results may be related to different properties of butyrate, i.e. either 
inducing protein hyperacetylation or inhibiting proteasome activity.  
The expression of IL-6 protein as well as expression of IL-6 and iNOS mRNAs were also 
enhanced by butyrate in N9 cells. On the basis of LDH leakage, this response was not toxic to 
LPS-stimulated N9 cells. 
Other short-chain fatty acids, propionate, valerate and caproate, enhanced the LPS-induced 
inflammatory response of N9 cells but neither a protective nor a proinflammatory response 
could be observed when hippocampal slices were exposed to these compounds. 
 
5.4 Regulation of signaling pathways 
Inflammation is highly regulated by different signaling pathways where acetylation and 
phosphorylation are key players of protein modifications. These reversible chemical 
modifications switch "on" and "off" the enzymes that control the activity of genes that are 
responsible for the production of pro-and anti-inflammatory end-products. In Study IV we 
tried to shed some light on some of the presently poorly understood mechanisms of the 
multitude of signaling regulators. 
 
Toll-like receptors 
LPS is recognized by TLR4 on the cell membrane of microglial cells but also TLR2 is 
activated (Laflamme et al., 2001, Olson and Miller, 2004) . To determine whether other 
receptors of the Toll family might be involved in the regulation of inflammation, we treated 
N9 cells with different Toll ligands in Study IV. 
Treatment of N9 microglia with specific TLR2 ligands evoked no responses as judged by 
the secretion of IL-6. Flagellin, a specific ligand for TLR5 and a substance that can be found 
as an impurity in LPS products, increased the secretion of IL-6. This secretion was also 
strongly potentiated by TSA treatment.  A specific ligand for TLR9, ODN1826 (Schluesener 
et al., 2001), also increased the secretion of IL-6 and TSA treatment potentiated this response. 
(Study IV, fig. 1). 
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 When we compared the responses of Ultra-pure LPS and "normal" LPS, the IL-6 cytokine 
response was clearly lower with Ultra-pure LPS, though the potentiation obtained with TSA 
was very similar (Study IV, fig. 1). 
These results suggest that N9 cells perhaps do not contain TLR2 and the effect of LPS is 
mediated through TLR4. Furthermore, it seems that protein acetylation affects the 
inflammatory response down-stream to the level of Toll-like receptor. 
 
NF-κB 
The NF-kB signaling pathway, which is connected upstream to Toll-like and cytokine 
receptors (Medzhitov and Janeway, 2001), is probably the best characterized key player in 
inflammatory responses. Recent studies have also shown that HDACs can acetylate also non-
histone proteins, such as signaling proteins and transcription factors (Hubbert et al., 2002, Juan 
et al., 2000). In Studies I, II, III and IV, we addressed the question of how NF-kB might be 
involved in the regulation of inflammatory responses by treating cells and slices with several 
NF-kB- related compounds. 
  IKK-2 inhibitor IV, a specific inhibitor of IKK-2 (Podolin et al., 2005) and a compound 
able to inhibit the IKK-2 mediated, proinflammatory NF-kB signaling pathway, potently 
inhibited the un-potentiated LPS response as well as potentiated IL-6 responses, induced either 
with TSA or okadaic acid. IKK-2 inhibitor also inhibited the NO secretion in all treatments 
(Study IV, fig. 3). 
Dexamethasone, a glucocorticoid that inhibits NF-kB signaling (Scheinman et al., 1995) 
and induces an anti-inflammatory response, totally blocked both the LPS-induced and TSA-
potentiated responses both in N9 microglia and in hippocampal slice cultures (Study IV, fig. 3 
and fig. 4)). Dexamethasone also inhibited the okadaic acid –induced secretion of IL-6 and 
NO from hippocampal slices (see e.g. supplementary material 1.). 
The NF-κB inhibitors, CAPE and helenalin (Natarajan et al., 1996, Lyss et al., 1998) 
inhibited the nuclear DNA binding of the NF-κB complex and blocked the TSA induced 
potentiation of cytokine and NO responses of N9 cells (Study II, fig. 7 and fig. 8). The 
response of hippocampal slices to TSA and helenalin was similar to that seen in N9 cells, i.e. 
both IL-6 and NO levels were downregulated when helenalin was added to LPS/TSA-
stimulated slices (Study I, fig. 6). 
The LPS-stimulated NF-κB-binding capacity was downregulated when both N9 cells and 
hippocampal slices were treated simultaneously with butyrate (Study III, fig. 4 and fig. 8). 
This downregulation was observed also when N9 cells were pretreated with butyrate before 
LPS exposure. 
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TSA or okadaic acid treatments did not enhance the nuclear NF-kB DNA-binding activity 
although they induced a prominent potentiation of IL-6 secretion by LPS.  
When N9 microglia were transiently transfected with the pNF-kB-Luc vector, the control 
pTal-Luc vector showed a minimal Luc reaction with all treatments but the NF-kB sites at the 
enhancer of the Luc vector potentiated the responses (Study IV, fig. 9B). Furthermore, TSA 
treatment also enhanced the expression of vector in control samples but especially in LPS 
treated N9 microglia, implying that the extent of the proinflammatory response attained by 
hyperacetylation is attributable to the enhancement of transactivation of the NF-kB driven 
inflammatory genes. 
These results reveal that indeed NF-kB is involved in various stages of inflammatory 
responses. Since NF-kB inhibitors strongly inhibited the TSA induced potentiation, it can be 
concluded that NF-kB signaling plays a role in the HDACi induced inflammatory response. 
However, as TSA did not affect the DNA-binding activity but a potentiation of IL-6 and iNOS 
mRNA expression could be observed, it seems that the proinflammatory responses enhanced 
by HDAC inhibitors may be under the regulation of transcriptional activity.  
 
PI-3K 
The PI-3-kinase pathway has been shown to be involved in TLR-signaling and in the 
networks regulating NF-kB activation (Hazeki et al., 2006). In particular, this pathway plays a 
role in the NF-kB mediated anti-inflammatory responses induced by glucocorticoids. In Study 
IV, we examined the effects of some well-known PI-3-kinase inhibitors, especially LY294002, 
in N9 cells and hippocampal slices. 
The PI-3-kinase inhibitor, LY294002 (Jung et al., 1999), inhibited the LPS-induced IL-6 
secretion and blocked the TSA-induced potentiation of IL-6 secretion (Study IV, fig. 7A). The 
inhibitory effect of LY294002 was not restricted to N9 microglia but occurred also in rat 
primary hippocampal slice cultures. It strongly inhibited the LPS-induced increase in IL-6 and 
NO secretion and blocked the TSA-induced potentiation of IL-6 secretion (Study IV, fig. 8). 
The DNA binding of the NF-κB complex in N9 microglia was not inhibited by LY294002 
(Study IV, fig. 9A), but the LPS-induced as well as the TSA-potentiated transactivation of NF-
kB-driven Luc reporter gene were both inhibited (Study IV, fig. 6). Moreover, okadaic acid 
induced potentiation of IL-6 secretion in N9 microglia was not affected by LY294002 (Study 
IV, fig. 7A). 
Based on these findings it seems that PI-3K is involved in the regulation of 
"hyperacetylation" via NF-κB but the okadaic acid induced phosphorylation response is 
mediated by some other signaling system. 
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Other signaling 
To search for other regulatory pathways and inhibitors for the pro-inflammatory 
potentiation induced by hyperacetylation, we also tested some additional well-known 
inhibitors of signal transduction. 
We examined several inhibitors, such as H7 (10 µM, final conc.), H89 (1.0 µM), PMA (200 
nM), JAK-3 inhibitor (1.0 µM), herbimycin (100 nM) and protein kinase Cζ pseudosubstrate 
inhibitor (1.0 µM) but none of these compounds significantly (p<0.01) altered the TSA-
induced potentiation at non-toxic concentrations. 
 
Remarks about  the results: 
There are some variations in the concentrations of different compounds tested with the 
different models. Some of the results show mild variance, most probably due to slight 
modifications in study designs occurring along the way. Nevertheless, all the results are in line 
to support the findings that the biological response to HDAC inhibitors was potentiation of 
LPS induced inflammation. Furthermore, hyperphosphorylation also potentiated this response, 
but the phenomenon occurred earlier. In addition, the observed potentiated response could be 
downregulated with specific blockers to NF-kB and PI-3K-mediated signaling . 
The number of cells in N9 cultures were affected by the different treatments, especially 
when okadaic acid was introduced to cells. On the other hand, the treatments did not have any 
effect on the total protein levels in cultures (see e.g. supplementary material 2.). 
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6. DISCUSSION 
 
6.1 Preface  
What is the role of inflammation in neurodegenerative diseases? Or conjointly, what is the 
role of microglia in neuroinflammation? These kinds of questions are definitely of great 
scientific interest in the field of neuroinflammation, but at the same time it must be stated that 
the answers are far from clear, being largely unresolved and a topic of intense debate.  
Terms like "a friend or foe", " the enemy within" and "double-edged sword" have been used 
when the role of microglia has been debated (Kempermann and Neumann, 2003, Lippoldt, 
Reichel and Moenning, 2005, Schenk and Yednock, 2002). The general assumption has been 
that the brain is in fact in an inflamed condition due to the overactive microglia which have 
been activated in the course of many neurological diseases. However, this view has been 
questioned and a different opinion proposed, i.e. the reason why microglia lose their ability to 
support neuronal functions is due to the fact that the senescence of these cells has occurred 
(Flanary, 2005). Nevertheless, much progress has taken place since the discovery of immunity 
by Mechnikov and his collaborators. Today the enigmatic nature of microglia as part of the 
brain's innate immune system is widely recognized. There is major interest on intracellular 
pathways e.g. down-stream regulators of the microglial inflammatory response. These studies 
have produced new information and many pieces have fitted into the jigsaw puzzle over the 
recent years. It may well be reasonable to state that the overall picture of microglial dynamics 
is beginning to take shape. 
We used different in vitro culture models, to examine whether manipulation of protein 
acetylation and phosphorylation status could change the microglial inflammatory responses 
and, if so, which players might be involved in transmitting these signals. The results 
strengthen the view that the outcome of both pro- and anti-inflammatory effects is tightly 
regulated and that the feedback responses are dependent on both the transcriptional activity of 
the inflammatory genes and the receptor system complexes that activate the signals of innate 
immunity. Furthermore, modification of proteins seems to be an important mechanism 
regulating inflammation. 
This discussion will focus on the interesting findings that inflammation can indeed be 
manipulated at different levels of a variety of signaling pathways, but before we will be able to 
design better anti-inflammatory drugs, a deeper understanding on the regulation of the 
intracellular signaling is needed.  
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6.2 Modulation of microglial response 
Treating neurodegenerative disorders with anti-inflammatory drugs may ameliorate the 
disease progression by altering the microglial response, as has been shown in animal models 
(Sastre, Klockgether and Heneka, 2006). Modulation of microglial activity by altering the 
regulation of these cells' intracellular signaling may be beneficial in a number of ways, for 
example by enhancing their ability to remove apoptotic cells or to release proteins that protect 
cells and promote cell growth. However, microglia may also contribute to inflammation by 
releasing cytokines or attracting and recruiting immune-system cells that lead to inflammation 
in the long term.  
The different neural inflammatory models revealed that an increase in protein acetylation 
leads to a proinflammatory response in transformed microglia as well as in cultured primary 
microglia. Since the potentiation of the inflammatory response after HDACi induction was 
observed also in neural co-cultures and hippocampal slice cultures, we conclude that the effect 
of the inhibitor (TSA) was not restricted to transformed cells and glial-neurone interactions did 
not, at least significantly, limit the response. This conclusion is supported by the recent 
findings of some other groups, for example, TSA has been shown to enhance LPS-induced 
expression of the Cox-2 gene in murine bone marrow-derived macrophages (Aung et al., 
2006).  
Similarly, enhancement of protein phosphorylation evoked a proinflammatory reaction but 
the response appeared as soon as 6 hours after exposure whereas at the same time TSA 
actually inhibited the LPS-induced response in IL-6 secretion. Up to the time point of 12 h, 
TSA caused a significant inhibition of IL-6 secretion but subsequently it induced an 
exponential increase in cytokine and nitric oxide production. When both acetylation and 
phosphorylation were enhanced simultaneously with compounds affecting the separate 
pathways, the inflammatory response showed synergistic potentiation. These findings clearly 
indicate that the overall acetylation and phosphorylation mediated immune responses are 
governed by different signaling pathways. Furthermore, we propose that the aforementioned 
potentiation of the inflammatory response by either "hyperacetylation" or 
"hyperphosphorylation" is attributable to the enhancement of transactivation of NF-kB driven 
inflammatory genes. Moreover, our studies imply that increase in the DNA-binding activity of 
NF-kB is necessary for the inflammatory response to occur, but the acetylation specifically 
seems to regulate the extent of the inflammatory response. 
The proinflammatory responses could be inhibited by using blockers targeted against the 
different signaling pathways. For example, dexamethasone proved to be profoundly anti-
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inflammatory against both TSA (acetylation) and okadaic acid (phosphorylation) induced 
potentiation, as well as against the LPS response itself. Furthermore, the TSA induced 
proinflammatory response could be blocked with the PI-3K inhibitor LY294002. Also NF-kB 
inhibitors such as helenalin and CAPE, and also butyrate, a SCFA, exerted anti-inflammatory 
properties by downregulating cytokine expression. 
It has been previously shown that the site-specific acetylation of p65 component increases 
the transactivation capacity of NF-κB complex (Chen and Greene, 2003, Quivy and Van Lint, 
2004, Rahman et al., 2004). Also, Natoli et al. (2005) have shown that even the recruitment of 
NF-κB complex to the promoters of selected inflammatory genes is highly regulated and 
dependent on MAP kinases and histone acetylation (enhanced by TSA exposure). In addition, 
Avdi et al. (2002) have proposed a model where PP2A has a central role in the regulation of 
the c-Jun NH2-terminal kinase pathway. Hence, okadaic acid induced inflammatory 
potentiation might be linked to the priming of chromatin to the NF-κB complex binding, since 
this response was inhibited by NF-κB inhibitor and dexamethasone.  
 
6.3 Evaluation of models 
The foundation for fundamental understanding of how cells communicate lies in the 
deconvolution of the signaling pathways. As the treatment of diseases can be implemented at 
various levels of signal transduction, it is essential for targeted drug discovery to understand 
the overall pathways and to have the right cell based models in which these pathways can be 
dissected. 
In the present studies, the murine N9 microglial cell line represented a model with "quick'n 
easy" access to preliminary answers, i.e. the aim was to prioritize for further evaluation 
synthetic compounds showing selective inhibition or potentiation of the inflammatory 
response. The N9 cell line has been derived by retroviral immortalization of day 13 embryonic 
mouse brain cultures carrying an activated v-myc oncogene (Corradin et al., 1993). Such 
immortalized microglia can be maintained as a stable, substantially homogeneous cell line in 
vitro and they represent a good model for preliminary screening of new drug molecules aimed 
at treating inflammation. The advantages of these cells are that they express typical markers of 
resting mouse microglia and they may be stimulated, in a similar manner to primary microglia, 
to produce proinflammatory cytokines (Righi et al., 1989) and nitric oxide (Corradin et al., 
1993). However, immortalized cell lines often have abnormal characteristics compared to non-
transformed cells. For this reason, they are not good models of normal tissue. 
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In addition to the N9 cell line, we used different primary cultures and co-cultures of rat 
origin to further delineate the effects of the HDAC- and NF-κB-inhibitors. These intact cells 
provide a platform for measuring complex biological processes and screening for the effects of 
our drug candidates. By applying modern assay techniques, it is possible to monitor functions 
and analyze multiple-step pathways. Moreover, primary cultures and co-cultures can be used 
to determine regulation of gene expression in response to biological and pharmacological 
stimuli and to permit identification of new targets for drug discovery.  
There is one potential limitation of utilizing these cells in serial experiments and long-term 
research. As a result of replicative senescence, these cells undergo progressive changes in 
morphology, proliferation and biological activity. Because of this limitation, many research 
laboratories prefer to use transformed cell lines for their studies. 
To translate the findings from basic cellular research more feasibly, cell-based models need 
to mimic both the multicellular complexity and the 3-D organization of an organ. Therefore 
we extended our models to the tissue-specific 3-D organotypic slice culture of postnatal rat 
hippocampus. This model carries a significant advantage over 2-D models, i.e. since the 
laminar circuitry remains functional and the cytoarchitecture is fairly well preserved, these 
types of cultures offer the advantage of accommodating systematic experimental intervention 
in living tissue. Moreover, these tissue-specific organotypic models offer great potential for 
understanding the networks of cell-cell interactions involved in signal transduction. Thus, 
organotypic cultures allow for the design and development of drug therapies in an 
environment that mimics the situation in vivo better than other cell-based models.  
In my opinion, the strength of this thesis is that we used all the aforementioned models in 
sequence in order to delineate the overall microglial responses to different modulations of 
inflammatory stimuli. As our findings demonstrate, the models correlate well, in that they 
provided results that are comparable and in line with each other. Therefore I postulate that 
these models, used in combination, are well suited for revealing different biochemical immune 
responses in the area of basic neuroinflammation research.. 
Despite the advantages of the different culture models, it is clear that in vivo studies and 
species extrapolation still remain a necessity. Animal model studies provide the only 
opportunity to evaluate the pharmacodynamic effects of a candidate anti-inflammatory drug in 
the whole-animal setting. Specifically, it is important to determine prior to clinical trials what 
the overall effect the drug has on the recovery when given during various stages of 
inflammation. 
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 Nevertheless, to assist in answering these questions, validated cell-based models have a 
role to play in preliminary screening and only by using all of the available methods can 
accurate conclusions be drawn. 
 
6.4 Aging and inflammation 
Although many consider life extension as the desired outcome of longevity research, the 
pharmacologically-mediated prolongation of life is currently science fiction, thus making 
aging the ultimate challenge to quality of human life. Senescence is an irreversible state or 
process of aging characterized by a declining ability to combat infection and because of this, 
inflammation is the major risk factor for death in the elderly. Today, despite the fact that 
vaccines save the lives of more than 10 million people worldwide every year, bacterial 
infections are still responsible for nearly 20 % of all deaths. According to estimates by the 
World Health Organization WHO (The World Health Report 2004), nearly 11 million people 
worldwide still die each year from infections. 
Some researchers regard aging itself as a disease but it could be described also as a "rusting 
path" we all experience. One common pathway involved in aging is inflammation. As we 
grow older, inflammation starts to "rust" our bodies and systemic inflammation can evoke 
devastating consequences throughout the body (Caruso et al., 2004, Clowes, Riggs and 
Khosla, 2005, Griffin,2006, McEwen et al., 2005, McGeer, Klegeris and McGeer, 2005). 
Cellular senescence is a phenomenon where isolated cells demonstrate a limited ability to 
divide, yet remaining metabolically active, in the culture dish. Furthermore, they exhibit 
changes in morphology and function which may lead to age-related changes. As an example 
one only has to consider the difference between the supple skin of a child and the wrinkled 
skin of an old man.  
Organismal senescence is the aging of organisms that is generally characterized by a 
declining ability to respond to stress, increasing homeostatic imbalance and increased risk of 
disease. Because of this, death is the ultimate consequence of aging. 
Aging itself results in an increase  in the levels of inflammatory cytokines and a decline in 
the ability to fight against infections (Krabbe, Pedersen and Bruunsgaard, 2004, Plowden et 
al., 2004). When the cytokine blood profile is examined in the aged in a weakened condition, 
an excess level of one or more of the inflammatory cytokines is usually found. A growing 
consensus among scientists is that many common neurological disorders, including  
Parkinson's and Alzheimer's diseases, are all caused in part by a chronic inflammatory 
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syndrome. Also people with multiple degenerative disorders exhibit excess levels of pro-
inflammatory markers, e.g., TNF-a, IL-6, IL-1(b), or IL-8, in their blood.  
Furthermore, high levels of several inflammation-related markers are associated with 
diseases/syndromes such as insulin resistance, type 2 diabetes and obesity (Ahmad et al., 2006, 
Gogia and Agarwal, 2006). These levels have been shown to decline in association with 
increased levels of anti-inflammatory molecules after consumption of a low calorie diet 
(Clement et al., 2004). Interestingly, caloric restriction (CR) has been shown to be one of the 
most effective means of slowing the pace of aging and extending lifespan in different 
laboratory animals, ranging from worms and flies to rats and fish, possibly even non-human 
primates (Barrows and Kokkonen, 1982, Weindruch and Walford, 1988, Kemnitz et al., 1993, 
Bodkin et al., 1995, Lane et al., 1998). However, whether long-term calorie restriction with 
adequate nutrition slows aging in humans remains to be seen.  
The signaling pathways suggested to be the responsible mediators of the "anti-aging" 
effects induced by CR are the same that regulate inflammation. For example, upregulation of 
NF-κB is suppressed by CR via inhibition of IκB kinase activation (Chung et al., 2002). The 
beneficial effects of CR have also been linked to PI-3/AKT kinase and MAPK pathways (Gan 
et al., 2005, McCurdy, Davidson and Cartee, 2005). Although the mechanisms of actions are 
poorly understood, it seems possible that CR exerts these effects by preserving anti-oxidative 
and other defense mechanisms through these mediators. 
Based on animal models, many candidate genes have been proposed as having distinct 
influences on lifespan. Most of these genes are involved in immune-system regulation or 
metabolic processes, for example the age-1 gene (encoding the PI-3K), identified from the 
nematode Caenorhabditis elegans, shares  homology with the mammalian  insulin-IGF1-
pathway which eventually targets a transcription factor that regulates innate immunity. Two 
other genes, called methuselah (Drosophila melanogaster) and Indy (I'm not dead yet, 
Drosophila melanogaster and Xenopus oocytes) are also under intensive investigation. 
Mutations in these genes have been shown to result in an increase in the average lifespan of 
fruit flies, possibly as a consequence of altered energy metabolism (Knauf et al., 2006, Lin et 
al., 1998). Furthermore, results from a population-based genetic study of Swedish elderly 
indicate that a common polymorphisms in apolipoprotein E (APOE) gene have an influence on 
lifespan (Corder et al., 1996).  
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The recently described "longevity genes", sirtuins (the class III HDACs) (Guarente and 
Kenyon, 2000), have raised hopes of finding new ways to fight against aging related diseases 
linked to inflammation. These are enzymes that are found in almost all life forms from yeasts 
to mammals and they apparently play critical roles in a number of life processes. Some studies 
have indicated that low calorie diets increase sirtuin activity (Chen et al., 2005a, Guarente, 
2005), thus linking metabolism and aging. Increased activity of these enzymes is thought to 
induce defensive, survival programs in cells to allow the organism to battle against a stressful 
environment. Indeed, it has been shown in mixed cortical cultures containing neurons, 
astrocytes and microglia, that the overexpression of class III HDAC, SIRT1, inhibits NF-κB 
signaling and suppresses amyloid-β mediated toxicity (Chen et al., 2005). Furthermore, the 
same study revealed that addition of the SIRT1 activator, resveratrol, a polyphenol compound 
found in red wine, to the amyloid-β treated cultures increased the survival of neurons in the 
presence of microglia. Interestingly, resveratrol has been found to increase the lifespan in C. 
elegans by 14% and in D. melanogaster by 29% (Howitz et al., 2003, Wood et al., 2004).  
 The idea behind the quest for finding new therapies using sirtuins seems to be the same as 
with other HDACs - by specifically manipulating the activity of these enzymes one could 
either "switch on" or "shut down" the target genes and restore the appropriate levels of the 
specific protein involved.  
 
6.5 Therapeutic perspectives 
It has become increasingly clear that abnormalities in the HAT-HDAC balance, 
phosphorylation status and/or in the regulation of NF-κB pathway are involved in the 
pathogenesis of several inflammatory related diseases. Thus, in general, the therapeutic 
potential lies behind the intervention and the consequent restoration of the impaired 
homeostasis caused by  these mechanisms. 
Currently ongoing phase I/II clinical trials of several different "first generation" HDAC 
inhibitors, particularly in the field of oncology, have shown some promise but also adverse 
effects, such as unwanted side effects have been detected (Minucci and Pelicci, 2006). Since 
they are relatively unselective in their abilities to block the different classes of HDACs, their 
benefit is probably derived from general repression in gene activity followed by 
hyperacetylation. On the other hand, the outcome of using HDAC inhibitors might vary, e.g. 
depending for example on the different cell types or target tissue. Indeed, as we observed in 
Study III, butyrate (pre)treatment induced a proinflammatory response in transformed N9 
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cells, but in contrast was anti-inflammatory in primary microglial cells and in hippocampal 
slice cultures. 
  Trichostatin A has been shown to provoke anti-inflammatory responses by splenocytes in 
a knockout mouse model of systemic lupus erythematosus (Mishra et al., 2003) and in cultured 
murine mesangial cells (Yu et al., 2002), as judged by the production of IL-6 and NO. There is 
also in vivo evidence that SAHA can reduce LPS induced levels of circulating IL-6 and TNF-
α  (Leoni et al., 2002).  Instead, in our models both TSA and SAHA were clearly 
proinflammatory. This might seem to preclude the use of these inhibitors for the treatment of 
neural inflammation. On the other hand, in N9 cells, TSA seemed to be anti-inflammatory up 
to 12 h before "reverting" to being proinflammatory. Furthermore, we have also observed an 
anti-inflammatory feedback response when pretreating microglial cells with a low dose of 
TSA before LPS exposure (unpublished results). These inducing or inhibitory effects of TSA 
therefore seem to depend on the treatment protocol. 
A further prospect for possible therapeutic intervention is the cross-talk between 
phosphorylation and modulation of HDAC activity. Even though these interactions are not yet 
well understood, the research in this field represents a fascinating area of drug research and 
development. Thus, one of the true future challenges will be to learn the nature of the 
combinatorial HDAC-protein-DNA interactions, and furthermore, to understand how these 
interactions vary in different tissues and cell types. In fact, during our studies we found that 
the simultaneous treatments with TSA and okadaic acid induced an additive response in IL-6 
secretion in LPS-treated hippocampal slice cultures (unpublished results). Furthermore, both 
the TSA and okadaic acid induced responses were blocked with dexamethasone, implying that 
there is a possibility to modulate the synergistic effect of the inducers. Hence, a better 
understanding of the regulation of the prolonged activation of microglial NF-κB pathway may 
lead to the discovery of new types of blockers to treat chronic inflammatory conditions. On the 
other hand, suppression of NF-κB activity for long periods may turn out to be a ill-advised 
strategy since microglia play such a crucial role in the host defense responses. 
Nevertheless, the research with these "first generation" HDAC inhibitors has not been in 
vain. Expanding understanding gained from previous studies has paved the way for the 
development of the "second generation" inhibitors that will target specific HDAC isoenzymes 
(Ward et al., 2003). These selective inhibitor candidates hopefully will target the transcription 
of inflammatory related genes with improved specificity and, safety. 
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Though still in its infancy, identification of new molecules that affect the HDAC complexes 
is likely to lead to new therapies to treat a variety of inflammatory related diseases. 
 
6.6 Concluding remarks 
 
The Good Side of Inflammation 
The inflammatory response to tissue damage is of enormous value. By isolating the 
damaged area, mobilizing effector cells and molecules to the infection site, and — in the late 
stages — by promoting healing, inflammation acts to protect the body. In fact, our immune 
system has evolved to control pathogens, so proinflammatory responses are likely to be 
evolutionarily programmed to resist fatal infections. 
 
The Bad Side of Inflammation 
Often the inflammatory response is out of proportion to the threat it faces. In that case, the 
result can be more damage to the body than the agent itself would have produced. The many 
types of allergies as well of the autoimmune diseases are typical examples of maladaptive 
inflammation in response to what should have been a harmless, or at least a noninfectious, 
agent.  
 
Treating Inflammation 
Today, inappropriate inflammation is treated with steroids like the glucocorticoid cortisol 
and with nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin or ibuprofen. While 
these NSAIDs may slow the progression of some diseases, the feedback loops in the brain are 
clearly too complicated to allow for such simplistic approaches e.g. as needed in the treatment 
of such multi-factorial diseases like Alzheimer's disease.  
Studying the mechanisms of histone deacetylase inhibitors may offer the potential to 
develop better targeted drugs to treat different inflammatory diseases in the future. Perhaps 
most importantly, however, these drug candidates may be pioneers in the development of 
inhibitor therapies with synergistic efficacy, and highlight the need for obtaining a 
comprehensive perspective of the potential therapeutic drug target before effective treatments 
can be developed. 
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7. CONCLUSIONS 
 
Protein acetylation and phosphorylation, two major intracellular modification systems, are 
clearly important factors contributing to the regulation inflammatory responses also in the 
brain. Moreover, the brain can no longer be considered as an immunoprivileged organ and 
innate immunity, the first line of defence, serves and protects the brain, this being mediated 
through the resident immune cells of CNS, the microglia. 
 
The following conclusions can be drawn from this series of studies: 
 
1. The axis from cell membrane Toll-receptors to the production of a number of 
 inflammation-related proteins involves an intracellular signaling machinery 
 that is time and dose dependently regulated by phosphorylation and 
 acetylation. 
   
2. Microglial cells, the resident immune cells of the CNS, seem to be intimately 
 involved in the regulation of the inflammatory responses. These responses could be 
 modulated by using compounds that affect the acetylation and phosphorylation 
 status of  proteins.  
 
3. The methods and models applied in these studies are suitable for the preclinical 
 studies of potential drug candidates aimed at repressing excessive inflammation 
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 A. Okadaic acid potentiation of LPS induced IL-6 expression on hippocampal slices at 4 DIV 
after 12h and 24h of exposure. LPS concentration was 5 µg/ml and that of okadaic acid 20 
nM. * p< 0.05 
B. The effect of dexamethasone on LPS alone and LPS+okadaic acid induced IL-6 
expression on hippocampal slices at 4 DIV after 24h of exposure. LPS concentration was 5 
µg/ml and that of okadaic acid 30 nM. ** p< 0.01 
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The effect of different treatments on the (A) morphology, (B) number of cells and (C) the 
amount of protein in N9 cells. After the introduction of okadaic acid, the cells arrested their 
proliferation and cell size increased, which in turn seemed to affect the number of cells/well. 
Instead, the protein levels remained similar despite the different treatments. The treatment 
time was 24 h and concentrations were 40 nM for okadaic acid, 20 nM for TSA and 5 µg/ml 
for LPS.
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